

APTARGROUP INC  
Form 10-K  
February 26, 2010

**Table of Contents**

**United States Securities and Exchange Commission  
Washington, D.C. 20549**

**FORM 10-K**

**[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934  
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2009**

**OR**

**[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934  
FOR THE TRANSITION PERIOD FROM == TO ==**

**COMMISSION FILE NUMBER 1-11846  
AptarGroup, Inc.**

**DELAWARE**

**36-3853103**

**475 WEST TERRA COTTA AVENUE, SUITE E, CRYSTAL LAKE, ILLINOIS 60014**

**815-477-0424**

Securities Registered Pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Name of each exchange on which registered</b>
Common Stock \$.01 par value	New York Stock Exchange
Preferred Stock Purchase Rights	New York Stock Exchange

Securities Registered Pursuant to Section 12 (g) of the Act:

**NONE**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes  No

Edgar Filing: APTARGROUP INC - Form 10-K

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

The aggregate market value of the common stock held by non-affiliates as of June 30, 2009 was \$2,227,224,064.

The number of shares outstanding of common stock, as of February 23, 2010, was 67,845,524 shares.

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of the definitive Proxy Statement to be delivered to stockholders in connection with the Annual Meeting of Stockholders to be held May 5, 2010 are incorporated by reference into Part III of this report.

---

AptarGroup, Inc.

**FORM 10-K**

For the Year Ended December 31, 2009

INDEX

	<b>Page</b>
<b><u>Part I</u></b>	
<u>Item 1.</u> <u>Business</u>	1
<u>Item 1A.</u> <u>Risk Factors</u>	6
<u>Item 1B.</u> <u>Unresolved Staff Comments</u>	8
<u>Item 2.</u> <u>Properties</u>	9
<u>Item 3.</u> <u>Legal Proceedings</u>	9
<u>Item 4.</u> <u>Submission of Matters to a Vote of Security Holders</u>	9
<b><u>Part II</u></b>	
<u>Item 5.</u> <u>Market for Registrant's Common Equity, Related Stockholder Matters, Issuer Purchases of Equity Securities and Share Performance</u>	10
<u>Item 6.</u> <u>Selected Consolidated Financial Data</u>	12
<u>Item 7.</u> <u>Management's Discussion and Analysis of Consolidated Results of Operations and Financial Condition</u>	13
<u>Item 7A.</u> <u>Quantitative and Qualitative Disclosure about Market Risk</u>	26
<u>Item 8.</u> <u>Financial Statements and Supplementary Data</u>	27
<u>Item 9.</u> <u>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u>	55
<u>Item 9A.</u> <u>Controls and Procedures</u>	55
<u>Item 9B.</u> <u>Other Information</u>	55
<b><u>Part III</u></b>	
<u>Item 10.</u> <u>Directors, Executive Officers and Corporate Governance</u>	55
<u>Item 11.</u> <u>Executive Compensation</u>	56
<u>Item 12.</u> <u>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u>	56
<u>Item 13.</u> <u>Certain Relationships and Related Transactions, and Director Independence</u>	56
<u>Item 14.</u> <u>Principal Accounting Fees and Services</u>	56
<b><u>Part IV</u></b>	
<u>Item 15.</u> <u>Exhibits and Financial Statement Schedules</u>	56
	<u>Signatures</u>
	57
<u>EX-10.27</u>	
<u>EX-10.34</u>	
<u>EX-21</u>	

EX-23  
EX-31.1  
EX-31.2  
EX-32.1  
EX-32.2

i /ATR

2009 Form 10-K

---

**Table of Contents**

PART I

**ITEM 1. BUSINESS**

**BUSINESS OF APTARGROUP**

We are a leading global supplier of a broad range of innovative dispensing systems for the personal care, fragrance/cosmetic, pharmaceutical, household and food and beverage markets. We provide value-added dispensing systems (pumps, closures and aerosol valves) to global consumer product marketers allowing them to differentiate their products and meet consumers' need for convenience.

Our business was started in the late 1940s, manufacturing and selling aerosol valves in the United States, and has grown primarily through the acquisition of relatively small companies and internal expansion. We were incorporated in Delaware in 1992. In this report, we may refer to AptarGroup, Inc. and its subsidiaries as AptarGroup or the Company.

We have manufacturing facilities located throughout the world including North America, Europe, Asia and South America. We have over 5,000 customers with no single customer accounting for greater than 6% of our 2009 net sales.

Sales of our dispensing systems have traditionally grown at a faster rate than the overall packaging industry as consumers' preference for convenience has increased and product differentiation through packaging design has become more important to our customers. Consumer product marketers have converted many of their products to packages with dispensers that offer the benefit of enhanced shelf appeal, convenience, cleanliness or accuracy of dosage. We expect this trend to continue.

Pumps are finger-actuated dispensing systems that dispense a spray or lotion from non-pressurized containers. The style of pump used depends largely on the nature of the product being dispensed, from small, fine mist pumps used with perfume and pharmaceutical products to lotion pumps for more viscous formulas.

Closures are primarily dispensing closures but to a lesser degree can include non-dispensing closures. Dispensing closures are plastic caps, primarily for plastic containers such as bottles and tubes, which allow a product to be dispensed without removing the cap.

Aerosol valves dispense product from pressurized containers. The majority of the aerosol valves that we sell are continuous spray valves, with the balance being metered dose inhaler valves.

**AVAILABLE INFORMATION**

Our periodic and current reports are available, free of charge, through a link on the Investor Relations page of our website ([www.aptar.com](http://www.aptar.com)), as soon as reasonably practicable after the material is electronically filed with, or furnished to, the SEC. Also posted on our website are the charters for our Audit, Compensation, Governance and Executive Committees, our Governance Principles and our Code of Conduct. Within the time period required by the SEC and the New York Stock Exchange (NYSE), we will post on our website any amendment to or waiver to the Code of Conduct applicable to any executive officer or director. The information provided on our website is not part of this report and is therefore not incorporated herein by reference.

**DESCRIPTION OF APTARGROUP'S REPORTING SEGMENTS**

**FINANCIAL INFORMATION ABOUT SEGMENTS**

The Company operates in the packaging components industry, which includes the development, manufacture and sale of consumer product dispensing systems. We are organized into three reportable business segments. Operations that sell spray and lotion dispensing systems and accessories primarily to the personal care, fragrance/cosmetic and

household markets form the Beauty & Home segment. Operations that sell closures to each market served by AptarGroup form the Closures segment. Operations that sell dispensing systems to the pharmaceutical market form the Pharma segment. Each of these three business segments is described more fully below. A summary of revenue, by segment, from external customers, profitability and total assets for each of the last three years is shown in Note 17 to the Consolidated Financial Statements in Item 8 (which is incorporated by reference herein).

The Company announced that in 2010 we are undertaking a strategic realignment of its businesses under three market-focused business segments. The three new segments are Aptar Beauty + Home, Aptar Food + Beverage and Aptar Pharma. This new structure will make it easier for our customers to do business with us and will also broaden and accelerate the development of innovative new products with a global focus on market applications and consumer preferences.

### **BEAUTY & HOME**

The Beauty & Home segment is our largest segment in terms of revenue and total assets representing 50% and 47% of AptarGroup's Net Sales and Total Assets, respectively. The Beauty & Home segment primarily sells pumps and aerosol valves and accessories to the personal care and household and food/beverage markets and pumps and decorative components to the fragrance/cosmetic market. We believe we are the leading supplier of fragrance/cosmetic and personal care fine mist spray pumps worldwide and the second largest supplier of personal care lotion pumps worldwide. We believe we are also one of the largest continuous spray aerosol valve suppliers worldwide.

1 /ATR

2009 Form 10-K

---

## Table of Contents

**Fragrance/Cosmetic.** Sales to the fragrance/cosmetic market for Beauty & Home accounted for approximately 56% of the segment's total net sales in 2009. The fragrance/cosmetic market requires a broad range of pump dispensing systems to meet functional as well as aesthetic requirements. A considerable amount of research, time and coordination with the customers' development staff is required to qualify a pump for use with their products. Within the market, we expect the use of pumps to continue to increase, particularly in the cosmetics and sampling sectors of this market. In the cosmetic sector, packaging for certain products such as anti-aging lotions continues to undergo a conversion from non-dispensing to pump systems, which continues to provide us with growth opportunities. Our airless dispensing systems, spray and lotion sampling devices, and decorative capabilities will also provide growth opportunities.

**Personal Care.** Sales to the personal care market for Beauty & Home accounted for approximately 36% of the segment's total net sales in 2009. Personal care products include fine mist spray pumps, lotion pumps and continuous spray aerosol valves. Typical personal care spray pump applications include hair care, sun care and deodorant products. Typical lotion pump applications include skin moisturizers and soap. Typical personal care continuous aerosol valve applications include hair care products, deodorants, shaving cream and most recently sun care lotions. Our research and development teams continue to design unique accessories that increase the value of our continuous aerosol valve offerings. Further, our bag-on-valve technology continues to provide marketers with unparalleled functionality. This technology physically separates the propellant from the product to be dispensed. It offers improved integrity of the product content, prevents expulsion of the propellant into the atmosphere and allows spraying of the product in any position. Sun care, tooth gel and nasal saline applications are examples of product applications using this technology.

**Household.** Sales to the household market for Beauty & Home accounted for approximately 6% of the segment's total net sales in 2009. Household products primarily use either continuous or metered dose spray aerosol valves and to a lesser degree spray pumps. Applications for continuous spray valves include disinfectants, spray paints, insecticides and automotive products. Metered dose valves are used for air fresheners. Spray pump applications primarily include household and industrial cleaners.

**Food/Beverage.** Sales to the food/beverage market accounted for approximately 1% of segment net sales in 2009. We traditionally sell aerosol valves to this market for cooking sprays and oils and spray pumps for butter substitutes and certain salad dressings.

## **CLOSURES**

The Closures segment is our second largest segment in terms of revenue and total assets representing 27% and 18% of AptarGroup's Net Sales and Total Assets, respectively. We believe that we are the largest supplier of dispensing closures in the United States, and the second largest supplier in Europe. We primarily manufacture dispensing closures and, to a lesser degree, non-dispensing closures.

Sales of dispensing closures have grown as consumers worldwide have demonstrated a preference for a package utilizing the convenience of a dispensing closure. At the same time, consumer marketers are trying to differentiate their products by incorporating performance enhancing features such as no-drip dispensing, inverted packaging and directional flow to make packages simpler to use, cleaner and more appealing to consumers. Closures are primarily sold to the personal care, food/beverage and household markets.

**Personal Care.** Historically, the majority of our dispensing closure sales have been to the personal care market. Sales to the personal care market for Closures accounted for approximately 56% of the segment's total net sales in 2009. Products with dispensing closures include shampoos, shower gels and skin care lotions. While many personal care products in the U.S. and Europe have already converted from non-dispensing to dispensing closures, we expect to benefit from similar conversions in other geographic areas such as Eastern Europe (including Russia), Latin America and Asia. Recent product innovations serving this market include large, wide mouth, easy open jar closures with



hinged lids and a push-open closure for various products.

**Food/Beverage.** Sales to the food/beverage market for Closures accounted for approximately 34% of the segment's total net sales in 2009. Sales of dispensing closures to the food/beverage market have increased significantly over the last several years as we continue to see an increase of interest from food/beverage marketers using dispensing closures for their products. Examples of food/beverage products currently utilizing dispensing closures include condiments, salad dressings, syrups, honey, water and dairy creamers. We believe there are good growth opportunities in the food/beverage market reflecting the continued and growing acceptance in this market of our silicone valve dispensing technology, and additional conversion from traditional packages to packages using dispensing closure systems, in particular for the single serve non-carbonated beverage industry.

**Household.** Sales to the household market for Closures accounted for approximately 7% of the segment's total net sales in 2009. While we have had success worldwide in selling dispensing closures to this market, it has not represented a significant amount of total dispensing closure sales. Products utilizing dispensing closures include dishwashing detergents, laundry care products and household cleaners.

2 /ATR

2009 Form 10-K

---

## **Table of Contents**

**Fragrance/Cosmetic.** Sales to the fragrance/cosmetic market are not a significant part of Closures sales (approximately 1% of segment net sales in 2009), but are mentioned here as an example of potential growth areas for the Closures segment. We are optimistic that we will increase sales to this market with our recent introduction of our Pinpoint dispensing closure with a conical shaped silicone valve tip targeted at cosmetic applications, in particular for eye creams and other applications requiring precise application.

### **PHARMA**

While the Pharma segment is our third largest segment in terms of revenue and total assets, accounting for 23% and 18% of AptarGroup's Net Sales and Total Assets, respectively, it is our most profitable segment. We believe we are the leading supplier of pumps and metered dose inhaler valves ( MDI s ) to the pharmaceutical market worldwide. Characteristics of this market include (i) governmental regulation of our pharmaceutical customers, (ii) contaminant-controlled manufacturing environments, and (iii) a significant amount of time and research from initially working with pharmaceutical companies at the molecular development stage of a medication through the eventual distribution to the market. We have clean-room manufacturing facilities in Argentina, China, France, Germany, Switzerland and the United States. We believe that the conversion from traditional medication forms such as pills and syringes to value-added, convenient dispensing will continue to increase.

Pumps sold to the pharmaceutical market deliver medications nasally, orally or topically. Currently the majority of our pumps sold are for allergy, cold or flu treatments. Potential opportunities for conversion from pills and syringes to pump dispensing systems include treatment for vaccines, additional cold and flu treatments, hormone replacement therapies, breakthrough pain medication and ophthalmic applications.

MDI s are used for dispensing precise amounts of medication. This aerosol technology allows medication to be broken up into very fine particles, which enables the drug to be delivered typically via the pulmonary system. We work with pharmaceutical companies as they work to phase out the use of chlorofluorocarbon ( CFC ) propellants. We continue to increase our market share of MDI s to this market as pharmaceutical companies replace CFC s with alternative propellants and we expect our market share to continue to grow. Currently the majority of our MDI s sold are used for respiratory ailments.

We continue to work on new dispensing systems and accessories in this segment such as a dose indicator feature for our MDI s to let the patient know exactly how many doses are left in the container. Also, we have developed a unique delivery system which dispenses a consistent dosage independent of the force and speed of actuation. We are also developing devices featuring lock-out technologies and other ophthalmic applications. While we expect that these new products will come to market in the future, it is difficult to estimate when as the rigors of pharmaceutical regulations affect the timing of product introductions by our pharmaceutical customers which use our dispensing systems.

## **GENERAL BUSINESS INFORMATION**

### **GROWTH STRATEGY**

We seek to enhance our position as a leading global supplier of innovative dispensing systems by (i) expanding geographically, (ii) converting non-dispensing applications to dispensing systems, (iii) replacing current dispensing applications with our dispensing products and (iv) developing or acquiring new dispensing technologies.

We are committed to expanding geographically to serve multinational customers in existing and emerging areas. Targeted areas include Asia, South America, and Eastern Europe. In 2007, we opened a new manufacturing facility in Thailand. In 2008, we opened a new larger facility in Brazil to expand our injection molding and decorating (including serigraphy and hot stamping) of plastic accessories primarily for the fragrance and cosmetic markets. In 2009, we acquired a Brazilian company which supplies anodized aluminum parts to other companies within the Company.

We believe significant opportunities exist to introduce our dispensing systems to replace non-dispensing applications. Examples of these opportunities include potential conversion in the food/beverage market for single serve non-carbonated beverages, condiments, and cooking oils. In the fragrance/cosmetic market, potential conversion includes creams and lotions currently packaged in jars or tubes using removable non-dispensing closures, converting

to lotion pumps or dispensing closures. We have developed and patented a thin sprayable dispensing system that can be inserted into magazines to replace the traditional scent strips. We believe this new innovative system will offer growth opportunities, particularly for fragrance samples. We have also developed a similar miniature flat sample for viscous creams as well as a small pump for use on vials for cosmetic lotions.

In addition to introducing new dispensing applications, we believe there are significant growth opportunities in converting existing pharmaceutical delivery systems (syringes or pills) to our more convenient dispensing pump or metered dose aerosol valve systems. Examples of opportunities in the pharmaceutical market include ways to dispense treatments for pulmonary conditions, vaccines, cold and flu treatments and hormone replacement therapies.

We are committed to developing or acquiring new dispensing technologies. Several years ago, we acquired intellectual property (patents, licenses and know how) and equipment relating to certain dry powder dispensing systems. We continue to develop this new technology and hope to have a product to market in the future. In 2008 we acquired a contract service organization specializing in analytical testing of nasal and inhalation products on behalf of pharmaceutical, biotech, drug delivery and device companies. We have entered into several exclusive licensing arrangements with third party innovators allowing us to continue to develop new dispensing systems using their technologies which are in various stages of development. We have also acquired businesses that manufacture aerosol valves with bag-on-valve technology. These systems physically

3 /ATR

2009 Form 10-K

---

## **Table of Contents**

separate the propellant from the product to be dispensed. It offers improved integrity of the product content, prevents expulsion of the propellant into the atmosphere and allows spraying of the product in any position. We also acquired three companies that manufacture decorative packaging components primarily for the high end of the fragrance/cosmetic market. This technology includes advanced molding capabilities as well as decoration (vacuum metallization and varnishing) of plastic components.

### **RESEARCH AND DEVELOPMENT**

One of our competitive strengths is our commitment to innovation and providing innovative dispensing solutions for our customers. This commitment to innovation is the result of our emphasis on research and development. Our research and development activities are directed toward developing innovative dispensing systems, adapting existing products for new markets or customer requirements, and reducing costs. We have research and development organizations located in the United States, France, Germany and Italy. In certain cases, our customers share in the research and development expenses of customer initiated projects. Occasionally, we acquire or license from third parties technologies or products that are in various stages of development. Expenditures for research and development activities net of a French R&D credit were \$50.2 million, \$55.1 million and \$53.7 million in 2009, 2008 and 2007, respectively.

### **PATENTS AND TRADEMARKS**

We customarily seek patent and trademark protection for our products and currently own and have numerous applications pending for United States and foreign patents and trademarks. In addition, certain of our products are produced under patent licenses granted by third parties. We believe that we possess certain technical capabilities in making our products that make it difficult for a competitor to duplicate.

### **TECHNOLOGY**

Pumps and aerosol valves require the assembly of up to 15 different plastic, metal and rubber components using high-speed equipment. When molding dispensing closures, or plastic components to be used in pump or aerosol valve products, we use advanced plastic injection molding technology, including large cavitation plastic injection molds. We are able to mold within tolerances as small as one one-thousandth of an inch and we manufacture products in a high-speed, cost-effective manner. Our injection molding capabilities include recent advances such as spin-stack and cube molding which utilizes high-efficiency rotating molds. We are also utilizing In-Molding Assembly Technology (IMAT) which allows us to assemble products within the molding process. We have experience in liquid silicone rubber molding that we utilize in our dispensing closure operations and certain of our pump products. We also have technology to decorate plastic and metal components sold primarily to the fragrance/cosmetic and personal care markets as well as rubber gasket formulation and production technology primarily for the pharmaceutical markets.

### **MANUFACTURING AND SOURCING**

More than half of our worldwide production is located outside of the United States. In order to augment capacity and to maximize internal capacity utilization (particularly for plastic injection molding), we use subcontractors to supply certain plastic, metal and rubber components. Certain suppliers of these components have unique technical abilities that make us dependent on them, particularly for aerosol valve and pump production. The principal raw materials used in our production are plastic resins and certain metal products. We believe an adequate supply of such raw materials is available from existing and alternative sources. We attempt to offset cost increases through improving productivity and increasing selling prices over time, as allowed by market conditions. Our pharmaceutical products often use specifically approved plastic resin for our customers. Significant delays in receiving components from these suppliers or discontinuance of an approved plastic resin would require us to seek alternative sources, which could result in higher costs as well as impact our ability to supply products in the short term.

### **SALES AND DISTRIBUTION**

Sales of products are primarily through our own sales force. To a limited extent, we also use the services of independent representatives and distributors who sell our products as independent contractors to certain smaller customers and export markets.

#### **BACKLOG**

Our sales are primarily made pursuant to standard purchase orders for delivery of products. While most orders placed with us are ready for delivery within 120 days, we continue to experience a trend towards shorter lead times requested by our customers. Some customers place blanket orders, which extend beyond this delivery period. However, deliveries against purchase orders are subject to change, and only a small portion of the order backlog is noncancelable. The dollar amount associated with the noncancelable portion is not material. Therefore, we do not believe that backlog as of any particular date is an accurate indicator of future results.

#### **CUSTOMERS**

The demand for our products is influenced by the demand for our customers' products. Demand for our customers' products may be affected by general economic conditions and liquidity, government regulations, tariffs and other trade barriers. Our customers include many of the largest personal care, fragrance/cosmetic, pharmaceutical, household and food/beverage marketers in the world. We have over 5,000 customers with no single customer accounting for greater than 6% of 2009 net sales. A consolidation of our customer base has occurred. This trend is expected to continue. A concentration of customers may

4 /ATR

2009 Form 10-K

---

## **Table of Contents**

result in pricing pressures or a loss of volume. However, this situation also presents opportunities for increasing sales due to the breadth of our product line, our international presence and our long-term relationships with certain customers.

### **INTERNATIONAL BUSINESS**

A significant number of our operations are located outside the United States. Sales in Europe for the years ended December 31, 2009, 2008 and 2007 were approximately 58%, 62% and 63%, respectively, of net sales. We manufacture the majority of units sold in Europe at facilities in the Czech Republic, England, France, Germany, Ireland, Italy, Russia, Spain and Switzerland. Other countries in which we operate include Argentina, Brazil, Canada, China, India, Indonesia, Japan, Mexico and Thailand which when aggregated represented approximately 14%, 12% and 11% of our consolidated sales for the years ended December 31, 2009, 2008 and 2007, respectively. Export sales from the United States were \$104.5 million, \$100.1 million and \$95.3 million in 2009, 2008 and 2007, respectively. For additional financial information about geographic areas, please refer to Note 17 in the Notes to the Consolidated Financial Statements in Item 8 (which is incorporated by reference herein).

### **FOREIGN CURRENCY**

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign entities. Our primary foreign exchange exposure is to the Euro, but we have foreign exchange exposure to the British Pound, Swiss Franc, South American and Asian currencies, among others. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge booked transactions and firm purchase and sales commitments denominated in foreign currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Changes in exchange rates on such inter-country sales could materially impact our results of operations.

### **WORKING CAPITAL PRACTICES**

Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. Historically, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements.

### **EMPLOYEE AND LABOR RELATIONS**

AptarGroup has approximately 8,700 full-time employees. Of the full-time employees, approximately 1,900 are located in North America, 5,200 are located in Europe and the remaining 1,600 are located in Asia and South America. Approximately 165 of the North American employees are covered by a collective bargaining agreement, while the majority of our European employees are covered by collective bargaining arrangements made at either the local or national level in their respective countries. Termination of employees at certain of our international operations could be costly due to local regulations regarding severance benefits. There were no material work stoppages in 2009 and management considers our employee relations to be satisfactory.

### **COMPETITION**

All of the markets in which we operate are highly competitive and we continue to experience price competition in all product lines and markets. Competitors include privately and publicly held entities. Our competitors range from regional to international companies. We expect the market for our products to remain competitive. We believe our competitive advantages are consistent high levels of innovation, quality and service, geographic diversity and breadth of products. Our manufacturing strength lies in the ability to mold complex plastic components in a cost-effective manner and to assemble products at high speeds. Our business is capital intensive and it is becoming more important to our customers to have global manufacturing capabilities. Both of these act as barriers to entry for new competitors wanting to enter our business.

While we have experienced some competition from low cost Asian suppliers particularly in the low-end fragrance/cosmetic and personal care market, this has not been significant. Indirectly, some fragrance marketers are sourcing their manufacturing requirements including filling of their product in Asia and importing the finished product back into the United States. However, some customers who had bought dispensing packaging products from low cost Asian suppliers in the past have reverted to purchasing our dispensing products again, citing the higher quality offered by our products and the logistical advantage of being closer to the customer.

### **ENVIRONMENT**

Our manufacturing operations primarily involve plastic injection molding and automated assembly processes and, to a limited degree, metal anodization and vacuum metallization of plastic components. Historically, the environmental impact of these processes has been minimal, and we believe we meet current environmental standards in all material respects. To date, our manufacturing operations have not been significantly affected by environmental laws and regulations relating to the environment.

Recently there is increased interest and awareness from the public and our customers in sustainability or producing sustainable products and measuring carbon footprints. Several organizations including the World Business Council for Sustainable Development in conjunction with scientists from the United Nations International Government Panel on Climate Change, have developed protocols to identify and calculate the amount of greenhouse gases manufacturing facilities generate. We are currently evaluating opportunities to become more energy efficient and lower greenhouse gas emissions, both of which reduce our carbon footprint.

5 /ATR

2009 Form 10-K

---

**Table of Contents****GOVERNMENT REGULATION**

Certain of our products are indirectly affected by government regulation. Growth of packaging using aerosol valves has been restrained by concerns relating to the release of certain chemicals into the atmosphere. Both aerosol and pump packaging are affected by government regulations regarding the release of volatile organic compounds ( VOC s ) into the atmosphere. Certain states within the United States have regulations that required the reduction in the amount of VOC s that can be released into the atmosphere and the potential exists for this type of regulation to expand worldwide. These regulations required our customers to reformulate certain aerosol and pump products, which may have affected the demand for such products. We own patents and have developed systems to function with alternative propellant and product formulations.

Future government regulations could include medical cost containment policies. For example, reviews by various governments to determine the number of drugs, or prices thereof, that will be paid by their insurance systems could affect future sales to the pharmaceutical industry. Such regulation could adversely affect prices of and demand for our pharmaceutical products. We believe that the focus on the cost effectiveness of the use of medications as compared to surgery and hospitalization provides us with an opportunity to expand sales to the pharmaceutical market. In general, government regulation of our customers' products could impact our sales to them of our dispensing systems.

**EXECUTIVE OFFICERS**

As discussed in the Description of AptarGroup's Reporting Segments in Item 1, Part I, the Company has announced that it is undertaking a strategic realignment of its businesses in 2010. To begin this realignment process, the Company has identified our leaders of the new segments below in the listing of executive officers as of February 26, 2010:

Name	Age	Position with the Company
<b>Peter Pfeiffer</b>	<b>61</b>	<b>President and Chief Executive Officer, AptarGroup, Inc.</b>
Mr. Peter Pfeiffer has been President and Chief Executive Officer since January 1, 2008 and was Vice Chairman of the Board since 1993.		
<b>Stephen Hagge</b>	<b>58</b>	<b>Executive Vice President and Chief Operating Officer, AptarGroup, Inc.</b>
Mr. Stephen Hagge has been Chief Operating Officer since January 1, 2008 and Executive Vice President since 1993. Prior to 2008, Mr. Hagge was Chief Financial Officer of AptarGroup.		
<b>Robert W. Kuhn</b>	<b>47</b>	<b>Executive Vice President and Chief Financial Officer, AptarGroup, Inc.</b>
Mr. Robert Kuhn has been Chief Financial Officer since September 30, 2008 and prior to this was Vice President Financial Reporting since 2000.		
<b>Olivier Fourment</b>	<b>52</b>	<b>President, Aptar Pharma</b>
Mr. Olivier Fourment has been President of Aptar Pharma since January 1, 2008 and was Co-President of Valois Group since 2000.		
<b>Olivier de Pous</b>	<b>65</b>	<b>Co-President, Aptar Beauty + Home</b>
On September 15, 2009, Mr. Olivier de Pous informed the Company of his intention to retire effective June 30, 2010. To aid in a smooth transition to the new segment structure, he became Co-President of Aptar Beauty + Home on January 1, 2010. Prior to 2010, Mr. de Pous had been President of Aptar Beauty & Home since January 1, 2008 and was Co-President of Valois Group since 2000.		
<b>Eric Ruskoski</b>	<b>62</b>	<b>President, Aptar Closures, Co-President, Aptar Beauty + Home, and Interim President, Aptar Food + Beverage.</b>
Mr. Eric Ruskoski has been President Aptar Closures since January 1, 2008 and was President of Seaquist Closures Group since 1987. On January 1, 2010 he also assumed responsibilities under the strategic realignment and was named Co-President, Aptar Beauty + Home, and Interim President, Aptar Food + Beverage.		
<b>Patrick Doherty</b>	<b>54</b>	<b>Co-President, Aptar Beauty + Home</b>



Mr. Patrick Doherty has been Co-President of Aptar Beauty + Home since January 1, 2010. Prior to 2010, Mr. Doherty served as President of SeaquistPerfect Dispensing Group since 2000.

There were no arrangements or understandings between any of the executive officers and any other person(s) pursuant to which such officers were elected.

### **ITEM 1A. RISK FACTORS**

Set forth below and elsewhere in this report and in other documents we file with the Securities and Exchange Commission are risks and uncertainties that could cause our actual results to materially differ from the results contemplated by the forward-looking statements contained in this report and in other documents we file with the Securities and Exchange Commission. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also impair our business operations. You should carefully consider the following factors in addition to other information contained in this report on Form 10-K before purchasing any shares of our common stock.

6 /ATR

2009 Form 10-K

---

**Table of Contents**

**FACTORS AFFECTING OPERATIONS OR OPERATING RESULTS**

**If we experience a long-term global recession, our business and operating results could be materially adversely impacted.** Due to our strong balance sheet, diverse product offerings, various end-markets served, and our broad geographic presence, we are well positioned to withstand slowness in any one particular region or market. However, given the continued uncertainty in global credit and financial markets (including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability), there can be no assurance that there will not be further deterioration in economic conditions. These economic uncertainties affect businesses such as ours in a number of ways, making it difficult to accurately forecast and plan our future business activities. The continued tightness of credit in financial markets may lead consumers and businesses to postpone spending, which may cause our customers to cancel, decrease or delay their existing and future orders with us. In addition, financial difficulties experienced by our suppliers, customers or distributors could result in product delays, increased accounts receivable defaults and inventory or supply challenges. Some of our materials are single-sourced. An interruption in supply would also impact our ability to meet customer demands. The continuing disruption in the credit markets has severely restricted access to capital. As a result, the ability to incur additional indebtedness to fund operations or refinance maturing obligations as they become due may be significantly constrained. We are unable to predict the likely duration and severity of the current disruptions in the credit and financial markets and adverse global economic conditions, and if the current uncertain economic conditions continue or further deteriorate, our business and results of operations could be materially and adversely affected. Furthermore, it is not certain whether the duration or current economic uncertainty of the crisis will be severe enough to cause a permanent shift in consumer behavior leading to reduced spending on grooming products and a substitution of economic utility over convenience.

**In difficult market conditions, our high fixed costs combined with potentially lower revenues may negatively impact our results.** Our business is characterized by high fixed costs and, notwithstanding our utilization of third-party manufacturing capacity, most of our production requirements are met by our own manufacturing facilities. In difficult industry environments, we are generally faced with a decline in the utilization rates of our manufacturing facilities due to decreases in product demand. During such periods, our plants do not operate at full capacity and the costs associated with this excess capacity are charged directly to cost of sales. The market conditions in the future may continue to adversely affect our utilization rates and consequently our future gross margins, and this, in turn, could have a material negative impact on our business, financial condition and results of operations.

**We face strong global competition and our market share could decline.** All of the markets in which we operate are highly competitive and we continue to experience price competition in all product lines and segments. Competitors include privately and publicly held entities. Our competitors range from regional to international companies. While we have experienced some competition from low cost Asian suppliers in some of our markets, particularly in the low-end fragrance/cosmetic and personal care market, this has not been significant. Indirectly, some fragrance marketers are sourcing their manufacturing requirements including filling of their product in Asia and importing the finished product back into the United States and Europe. If we are unable to compete successfully, our market share may decline, which could materially adversely affect our results of operations and financial condition.

**We have foreign currency translation and transaction risks that may materially adversely affect our operating results.** A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign entities. Our primary foreign exchange exposure is to the Euro, but we have foreign exchange exposure to South American and Asian currencies, among others. We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain transactions and firm purchase and sales commitments denominated in foreign currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. The volatility of currency exchange rates may

materially affect our operating results.

**If our unionized employees were to engage in a strike or other work stoppage, our business and operating results and financial condition could be materially adversely affected.** Approximately 165 of our North American employees are covered by a collective bargaining agreement, while the majority of our European employees are covered by collective bargaining arrangements made either at the local or national level in their respective countries. Although we believe that our relations with our employees are satisfactory, no assurance can be given that this will continue. If disputes with our unions arise, or if our unionized workers engage in a strike or other work stoppage, we could incur higher labor costs or experience a significant disruption of operations, which could have a material adverse effect on our business, financial position and results of operations.

**If we were to incur a significant product liability claim above our current insurance coverage, our operating results and financial condition could be materially adversely affected.** Approximately 23% of our net sales are made to customers in the pharmaceutical industry. If our devices fail to operate as intended, medication prescribed for patients may be under administered, or may be over administered. The failure of our devices to operate as intended may result in a product liability claim against us. We believe we maintain adequate levels of product liability insurance coverage. A product liability claim

7 /ATR

2009 Form 10-K

---

## **Table of Contents**

or claims in our Pharma segment or our other segments in excess of our insurance coverage may materially adversely affect our business, financial position and results of operations.

**The success or failure of our customers' products, particularly in the pharmaceutical market, may materially affect our operating results and financial condition.** In the pharmaceutical market, the proprietary nature of our customers' products and the success or failure of their products in the market using our dispensing systems may have a material impact on our operating results and financial condition. We may potentially work for years on modifying our dispensing device to work in conjunction with a customer's drug formulation. If the customer's product is not successful on the market, the time spent may not be recovered. On the contrary, a successful product launch from one of our pharmaceutical customers may have a material positive impact on our operating results and financial condition.

**Higher raw material costs and an inability to increase our selling prices may materially adversely affect our operating results and financial condition.** Raw material costs increased significantly over the past few years and we have generally been able to increase selling prices to cover increased costs. In the future, market conditions may prevent us from passing these increased costs on to our customers through timely price increases. In addition, we may not be able to improve productivity or realize our ongoing cost reduction programs sufficiently to help offset the impact of these increased raw material costs. As a result, higher raw material costs could result in declining margins and operating results.

**We have approximately \$231 million in recorded goodwill and changes in future business conditions could cause this asset to become impaired, requiring write-downs that would reduce our operating income.** We evaluate the recoverability of goodwill amounts annually, or more frequently when evidence of potential impairment exists. The impairment test is based on several factors requiring judgment. A decrease in expected reporting unit cash flows or changes in market conditions may indicate potential impairment of recorded goodwill and, as a result, our operating results could be materially adversely affected. See "Critical Accounting Policies and Estimates" in Part II, Item 7 (which is incorporated by reference herein).

**The scope and complexity of the change in organization structure could increase certain risks.** The Company has announced that in 2010 we are undertaking a strategic realignment in our businesses under three market-focused business segments. This realignment will allow us to offer our full product range in each of our three new segments: Aptar Beauty + Home, Aptar Food + Beverage and Aptar Pharma. The new structure will also broaden and accelerate the development of innovative new products with a global focus on market applications and consumer preferences. This realignment will take some time to complete and we expect to be fully operating under the new structure beginning in 2011. However, we could experience some planning and execution risks as employees handle multiple roles during this transition period.

### **FACTORS AFFECTING APTARGROUP STOCK**

**Ownership by Certain Significant Shareholders.** Neuberger Berman Inc. and State Farm Mutual Automobile Insurance Company each own approximately 12% and 9%, respectively, of our outstanding common stock. If one of these significant shareholders decides to sell significant volumes of our stock, this could put downward pressure on the price of the stock.

**Certain Anti-takeover Factors.** Certain provisions of our Certificate of Incorporation and Bylaws may inhibit changes in control of AptarGroup not approved by the Board of Directors. These provisions include (i) special voting requirements for business combinations, (ii) a classified board of directors, (iii) a prohibition on stockholder action through written consents, (iv) a requirement that special meetings of stockholders be called only by the board of directors, (v) advance notice requirements for stockholder proposals and nominations, (vi) limitations on the ability of stockholders to amend, alter or repeal our bylaws and (vii) provisions that require the vote of 70% of the whole Board of Directors in order to take certain actions.

**ITEM 1B. UNRESOLVED STAFF COMMENTS**

The Company has no unresolved comments from the SEC.

8 /ATR

2009 Form 10-K

---

**Table of Contents****ITEM 2. PROPERTIES**

We lease or own our principal offices and manufacturing facilities. None of the owned principal properties is subject to a lien or other encumbrance material to our operations. We believe that existing operating leases will be renegotiated as they expire, will be acquired through purchase options or that suitable alternative properties will be leased on acceptable terms. We consider the condition and extent of utilization of our manufacturing facilities and other properties to be generally good, and the capacity of our plants to be adequate for the needs of our business. The locations of our principal manufacturing facilities, by country, are set forth below:

***ARGENTINA***

Buenos Aires (1, 2 &amp; 3)

***BRAZIL***Sao Paulo (1 & 3)  
Maringá Paraná (1)***CHINA***

Suzhou (1, 2 &amp; 3)

***CZECH REPUBLIC***

Ckyne (3)

***FRANCE***Annecy (1 & 2)  
Charleval (1)  
Le Neubourg (1)  
Le Vaudreuil (2)  
Oyonnax (1 & 3)  
Poincy (3)  
Verneuil Sur Avre (1)***GERMANY***Böhringen (1)  
Dortmund (1)  
Eigeltingen (2)  
Freyung (3)  
Menden (1)***INDIA***

Himachal Pradesh (1)

***INDONESIA***

Cikarang, Bekasi (2)

***IRELAND***

Ballinasloe, County Galway (1)

***ITALY***Manoppello (1)  
Milan (1)  
San Giovanni Teatino (Chieti) (1)***MEXICO***

Queretaro (1 &amp; 3)

***RUSSIA***

Vladimir (3)

***SWITZERLAND***Messovico (2)  
Neuchâtel (1)***SPAIN***

Torello (3)

***THAILAND***

Chonburi (1)

***UNITED KINGDOM***Leeds, England (3)  
Milton Keynes (1 & 2)***UNITED STATES***Cary, Illinois (1)  
Congers, New York (1 & 2)  
Libertyville, Illinois (3)  
McHenry, Illinois (1)  
Midland, Michigan (3)  
Mukwonago, Wisconsin (3)  
Stratford, Connecticut (1)  
Torrington, Connecticut (1)  
Watertown, Connecticut (1)

- (1) Locations of facilities manufacturing for the Beauty & Home segment.
- (2) Locations of facilities manufacturing for the Pharma segment.
- (3) Locations of facilities manufacturing for the Closures segment.

In addition to the above countries, we have sales offices or other manufacturing facilities in Canada and Japan. Our corporate office is located in Crystal Lake, Illinois.

**ITEM 3. LEGAL PROCEEDINGS**

Claims in the product liability and patent infringement areas, even if without merit, could result in the significant expenditure of our financial and managerial resources. It is possible that future results of operations or cash flows for any particular quarterly or annual period could be materially affected by an unfavorable resolution of such a claim.

**ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

None.

9 /ATR

2009 Form 10-K

---

Table of Contents

## PART II

**ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED  
STOCKHOLDER MATTERS, ISSUER PURCHASES OF EQUITY SECURITIES  
AND SHARE PERFORMANCE**

MARKET FOR REGISTRANT'S COMMON EQUITY

Information regarding market prices of our Common Stock and dividends declared may be found in Note 19 to the Consolidated Financial Statements in Item 8 (which is incorporated by reference herein). Our Common Stock is traded on the New York Stock Exchange under the symbol ATR. As of February 16, 2010, there were approximately 400 registered holders of record.

RECENT SALES OF UNREGISTERED SECURITIES

The employees of AptarGroup S.A.S. and Valois S.A.S., our subsidiaries, are eligible to participate in the FCP Aptar Savings Plan (the Plan). All eligible participants are located outside of the United States. An independent agent purchases shares of Common Stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of Common Stock under the Plan. The agent under the Plan is Banque Nationale de Paris Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended December 31, 2009, the Plan purchased 835 shares of our common stock on behalf of the participants at an average price of \$36.55 per share, for an aggregate amount of \$31 thousand. No shares were sold during the quarter. At December 31, 2009, the Plan owns 17,858 shares of our Common Stock.

ISSUER PURCHASES OF EQUITY SECURITIES

The following table summarizes the Company's purchases of its securities for the quarter ended December 31, 2009:

<b>Period</b>	<b>Total Number Of Shares Purchased</b>	<b>Average Price Paid Per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs</b>
10/1 - 10/31/09	148,871	\$ 36.85	148,871	4,015,576
11/1 - 11/30/09	180,292	35.95	180,292	3,835,284
12/1 - 12/31/09	171,417	36.49	171,417	3,663,867
<b>Total</b>	<b>500,580</b>	<b>\$ 36.40</b>	<b>500,580</b>	<b>3,663,867</b>

The Company announced the existing repurchase program on July 19, 2006. There is no expiration date for this repurchase program.





**Table of Contents**

**SHARE PERFORMANCE**

The following graph shows a five year comparison of the cumulative total stockholder return on AptarGroup's common stock as compared to the cumulative total return of two other indexes: the Value Line Packaging & Container Industry Group ( Peer Group ) and the Standard & Poor's 500 Composite Stock Price Index. The companies included in the Peer Group are: AptarGroup, Inc., Ball Corporation, Bemis Company, Inc., CLARCOR Inc., Crown Holdings, Inc., Greif, Inc., Mead Westvaco, Owens-Illinois, Inc., Packaging Corporation of America, Pactiv Corporation, Rock-Tenn Company, Sealed Air Corporation, Silgan Holdings, Inc., and Sonoco Products Company. Changes in the Peer Group from year to year result from companies being added to or deleted from the Value Line Packaging & Container Industry Group. These comparisons assume an initial investment of \$100 and the reinvestment of dividends.

**Comparison of 5 Year Cumulative Stockholder Returns**

The graph and other information furnished in the section titled Share Performance under this Part II, Item 5 of this Form 10-K shall not be deemed to be soliciting material or to be filed with the Securities and Exchange Commission or subject to Regulation 14A or 14C, or to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended.

11 /ATR

2009 Form 10-K

---

**Table of Contents****ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA****FIVE YEAR SUMMARY OF SELECTED FINANCIAL DATA****In millions of dollars, except per share data**

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>	<b>2006</b>	<b>2005</b>
<b>Statement of Income Data:</b>					
Net Sales	\$ <b>1,841.6</b>	\$ 2,071.7	\$ 1,892.2	\$ 1,601.4	\$ 1,380.0
Cost of Sales (exclusive of depreciation shown below) (1)	<b>1,225.7</b>	1,411.3	1,283.8	1,086.3	927.6
% of Net Sales	<b>66.6%</b>	68.1%	67.9%	67.8%	67.2%
Selling, Research & Development and Administrative (2)	<b>276.9</b>	295.1	272.1	236.9	202.2
% of Net Sales	<b>15.0%</b>	14.2%	14.4%	14.8%	14.6%
Depreciation and Amortization	<b>133.0</b>	131.1	123.5	114.6	99.2
% of Net Sales	<b>7.2%</b>	6.3%	6.5%	7.2%	7.2%
Facilities consolidation and severance	<b>7.6</b>				
% of Net Sales	<b>.4%</b>				
Operating Income	<b>198.4</b>	234.2	212.9	163.6	151.0
% of Net Sales	<b>10.8%</b>	11.3%	11.3%	10.2%	10.9%
Income from Continuing Operations (3)	<b>124.6</b>	153.5	139.5	102.9	100.0
% of Net Sales	<b>6.8%</b>	7.4%	7.4%	6.4%	7.3%
Income from Discontinued Operations					
Net of Tax			2.2		
% of Net Sales			0.1%		
Net Income (3)	<b>124.6</b>	153.5	141.7	102.9	100.0
% of Net Sales	<b>6.8%</b>	7.4%	7.5%	6.4%	7.3%
<b>Net Income per Common Share (Basic):</b>					
Continuing Operations (4)	\$ <b>1.84</b>	\$ 2.26	\$ 2.03	\$ 1.48	\$ 1.42
Discontinued Operations (4)			.03		
Net Income per Common Stock (Basic)	<b>1.84</b>	2.26	2.06	1.48	1.42
<b>Net Income per Common Stock (Diluted):</b>					
Continuing Operations (4)	<b>1.79</b>	2.18	1.95	1.44	1.39
Discontinued Operations (4)			.03		
Net Income per Common Share (Diluted)	<b>1.79</b>	2.18	1.98	1.44	1.39
Cash Dividends Declared per Common Share	<b>.60</b>	.56	.50	.42	.35
<b>Balance Sheet and Other Data:</b>					
Capital Expenditures	\$ <b>144.9</b>	\$ 203.6	\$ 137.9	\$ 107.7	\$ 104.4
Total Assets	<b>1,956.2</b>	1,831.8	1,911.9	1,592.0	1,357.3
Long-Term Obligations	<b>209.6</b>	226.9	146.7	168.9	144.5
Net Debt (5)	<b>5.0</b>	99.4	49.1	125.7	129.0

Edgar Filing: APTARGROUP INC - Form 10-K

AptarGroup, Inc. Stockholders Equity	<b>1,252.8</b>	1,131.0	1,119.0	946.4	809.4
Capital Expenditures % of Net Sales	<b>7.9%</b>	9.8%	7.3%	6.7%	7.6%
Interest Bearing Debt to Total Capitalization (6)	<b>21.2%</b>	20.4%	24.5%	23.8%	23.4%
Net Debt to Net Capitalization (7)	<b>0.4%</b>	8.1%	4.2%	11.7%	13.7%

- (1) Cost of Sales includes a charge for the expensing of stock options of \$1.1, \$1.1, \$1.0 and \$0.9 million in 2009, 2008, 2007 and 2006, respectively, and Redeployment Program costs \$1.6 and \$2.1 million in 2007 and 2006, respectively.
- (2) Selling, Research & Development and Administrative includes a charge of \$8.7, \$10.0, \$13.0 and \$12.4 million for the expensing of stock options in 2009, 2008, 2007 and 2006, respectively, and French R&D tax credit of \$5.7, \$2.1, \$2.0, and \$1.2 million in 2008, 2007, 2006 and 2005, respectively.
- (3) Net Income includes a charge for the expensing of stock options of \$7.3, \$8.0, \$10.5 and \$8.7 million in 2009, 2008, 2007 and 2006, respectively, and Redeployment Program costs of \$1.1 and \$1.4 million in 2007 and 2006, respectively.
- (4) Net Income per basic and diluted common share includes the negative effects of \$0.11, \$0.12, \$0.15 and \$0.12 for the expensing of stock options in 2009, 2008, 2007 and 2006, respectively, and \$0.02 and \$0.03 for Redeployment Program costs in 2007 and 2006, respectively
- (5) Net Debt is interest bearing debt less cash and cash equivalents.
- (6) Total Capitalization is AptarGroup, Inc. Stockholders Equity plus interest bearing debt.
- (7) Net Capitalization is AptarGroup, Inc. Stockholders Equity plus Net Debt.

12 /ATR

2009 Form 10-K

**Table of Contents**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

(In thousands, except per share amounts or otherwise indicated)

The objective of the following Management's Discussion and Analysis of Consolidated Results of Operations and Financial Condition ( MD&A ) is to help the reader understand the financial performance of AptarGroup, Inc. MD&A is presented in eight sections: Overview, Results of Operations, Off-Balance Sheet Arrangements, Overview of Contractual Obligations, Adoption of Accounting Standards, Critical Accounting Policies and Estimates, Operations Outlook and Forward-Looking Statements. MD&A should be read in conjunction with our consolidated financial statements and accompanying Notes to Consolidated Financial Statements contained elsewhere in this Report on Form 10-K.

In MD&A, we, our, us, AptarGroup, AptarGroup, Inc. and the Company refer to AptarGroup, Inc. and its subsidiaries.

**OVERVIEW**

**GENERAL**

We are a leading global supplier of a broad range of innovative dispensing systems for the personal care, fragrance/cosmetic, pharmaceutical, household and food/beverage markets. We focus on providing value-added dispensing systems (pumps, closures and aerosol valves) to global consumer product marketers to allow them to differentiate their products and meet consumers' need for convenience.

2009 was one of the most challenging years in our history but the strong fourth quarter results were encouraging. The global economic crisis touched all of our segments as consumer spending was greatly reduced. Also, our customers were cautious throughout most of the year and, as a result, they reduced their inventory levels particularly in the first half of the year. This caused order quantities to decline which hampered our ability to grow our sales. However, as we have done in the past, we managed to reduce costs without affecting our ability to quickly respond to our customers when the markets stabilize. Our operations in the developing countries did well as demand for our products remained strong in those regions and the continued conversion to convenient dispensing systems in the food and beverage markets was a positive driver for our Closures segment. The competitive pricing environment, faced particularly by our Beauty & Home and Closures segments, remained challenging throughout the year.

**2009 HIGHLIGHTS**

Sales volumes declined on general economic weakness, however all segments remained profitable.

Certain regions and markets stabilized in the second half of 2009 leading to improved sales and compared to over the first half.

Cost saving efforts favorably impacted our results.

Underutilized capacity negatively impacted Beauty & Home segment income.

Reported charges of \$7.6 million for facilities consolidation and other severance costs.

**Table of Contents****RESULTS OF OPERATIONS**

The following table sets forth the consolidated statements of income and the related percentages of net sales for the periods indicated:

Years Ended December 31,	2009		2008		2007	
	Amount in \$ Thousands	% of Net Sales	Amount in \$ Thousands	% of Net Sales	Amount in \$ Thousands	% of Net Sales
Net sales	\$ 1,841,616	100.0%	\$ 2,071,685	100.0%	\$ 1,892,167	100.0%
Cost of sales (exclusive of depreciation shown below)	1,225,670	66.6	1,411,275	68.1	1,283,773	67.9
Selling, research & development and administrative	276,989	15.0	295,094	14.2	272,077	14.4
Depreciation and amortization	133,013	7.2	131,145	6.3	123,466	6.5
Facilities consolidation and severance expense	7,563	0.4				
Operating income	198,381	10.8	234,171	11.3	212,851	11.2
Other expense	(14,323)	(0.8)	(7,445)	(0.4)	(10,770)	(0.5)
Income from continuing operations before income taxes	184,058	10.0%	226,726	10.9%	202,081	10.7%
Income from continuing operations	124,597	6.8%	153,501	7.4%	139,474	7.4%
Effective tax rate	32.3%		32.3%		31.0%	
Income from discontinued operations net of tax					2,232	0.1%

**NET SALES**

Net sales decreased more than 11% in 2009 to \$1.8 billion compared to \$2.1 billion recorded in 2008. The U.S. dollar strengthened against several currencies including the Euro (our primary foreign currency exposure) in 2009 compared to 2008, and as a result, changes in exchange rates negatively impacted sales and accounted for approximately 5% of

the 11% sales decline. Sales related to acquisitions were approximately \$12.9 million. The remaining 7% of sales decline was due primarily to the weakness of our Beauty & Home segment as fragrance/cosmetic sales were significantly impacted by the challenging general economic conditions in 2009. Pricing was also negatively impacted primarily due to lower resin pass-through to customers.

In 2008, net sales increased more than 9% in 2008 to nearly \$2.1 billion compared to \$1.9 billion recorded in 2007. The U.S. dollar weakened against several currencies including the Euro in 2008 compared to 2007, and as a result, changes in exchange rates positively impacted sales and accounted for approximately 4% of the 9% sales growth. Approximately \$9 million of the \$180 million increase in net sales (less than 1% of the 9% increase) related to acquisitions completed during 2008. The remaining 4% of sales growth was due primarily to the strength of our Pharma segment. Sales price increases were primarily pass-throughs of the raw material cost increases we incurred during the year.

For further discussion on net sales by reporting segment, please refer to the segment analysis of net sales and operating income on the following pages.

The following table sets forth, for the periods indicated, net sales by geographic location:

Years Ended December 31,	2009	% of Total	2008	% of Total	2007	% of Total
Domestic	\$ 519,671	28%	\$ 531,054	26%	\$ 498,231	26%
Europe	1,073,035	58%	1,288,667	62%	1,180,443	63%
Other Foreign	248,910	14%	251,964	12%	213,493	11%

#### **COST OF SALES (EXCLUSIVE OF DEPRECIATION SHOWN BELOW)**

Our cost of sales as a percentage of net sales decreased in 2009 to 66.6% compared to 68.1% in 2008.

The following factors positively impacted our cost of sales percentage in 2009:

**Cost Reduction Efforts.** We implemented cost reduction programs to bring costs in line with current production levels.

**Declining Resin Costs.** Resin costs declined during 2009 compared to 2008. While the majority of these input costs decreases are passed along to our customers in our selling prices, we experience a normal lag in the timing of passing on these cost decreases.

**Table of Contents**

**Strengthening of the U.S. Dollar.** We are a net importer from Europe into the U.S. and other countries of products produced in Europe with costs denominated in Euros. As a result, when the U.S. dollar or other currencies strengthen against the Euro, products produced in Europe (with costs denominated in Euros) and sold in currencies that are stronger compared to the Euro have a positive impact on cost of sales as a percentage of net sales.

**Favorable Product Mix.** Increases in the percentage of sales of our products to the pharmaceutical market, which traditionally generate higher margins, helped positively impact our cost of sales percentage in 2009.

The following factors negatively impacted our cost of sales percentage in 2009:

**Underutilized Overhead Costs in Certain Operations.** Several of our business operations, especially in the Beauty & Home business segment, saw a decrease in unit volumes sold. As a result of the lower production levels, overhead costs were underutilized, thus negatively impacting cost of goods sold as a percentage of net sales.

**Last in First Out ( LIFO ) Inventory Valuation.** Some of our U.S. operations use LIFO as their inventory valuation method. As some material costs, namely resins, increased at the end of the fourth quarter, the increase to the LIFO reserve in 2009 was approximately \$0.4 million, thus negatively impacting our cost of sales percentage in 2009.

In 2008, our cost of sales as a percentage of net sales increased slightly in 2008 to 68.1% compared to 67.9% in 2007.

The following factors negatively impacted our cost of sales percentage in 2008:

**Rising Input Costs.** Input costs, in particular resin, tinplate, utilities and transportation costs, continued to increase through the third quarter of 2008 over 2007, primarily in the U.S. and Europe, but also in the rest of the world. While we attempt to pass these rising input costs along in our selling prices we experience a lag in the timing of passing on these cost increases. We experienced decreases in certain material costs towards the end of the fourth quarter. However, the effects of these decreases do not offset the increases taken during the first nine months of the year.

**Weakening of the U.S. Dollar.** We are a net importer from Europe into the U.S. and other countries of products produced in Europe with costs denominated in Euros. As a result, when the U.S. dollar or other currencies weaken against the Euro, products produced in Europe (with costs denominated in Euros) and sold in currencies that are weaker compared to the Euro have a negative impact on cost of sales as a percentage of net sales.

**Underutilized Overhead Costs in Certain Operations.** Certain of our business operations in the Beauty & Home and Closures business segments saw a decrease in unit volumes sold and as a result of the lower production levels, overhead costs were underutilized, thus negatively impacting cost of goods sold as a percentage of net sales.

The following factors positively impacted our cost of sales percentage in 2008:

**Favorable Product Mix.** Increased sales of our products to the pharmaceutical market, which traditionally generate higher margins, helped positively impact our cost of sales percentage in 2008.

**Last in First Out ( LIFO ) Inventory Valuation.** As mentioned above, some of our U.S. operations use LIFO as their inventory valuation method. As some material costs, namely resins, dramatically decreased at the end of the fourth quarter, the decrease to the LIFO reserve in 2008 was approximately \$2.3 million, thus positively impacting our cost of sales percentage in 2008.

**SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE**



Our Selling, Research & Development and Administrative expenses ( SG&A ) decreased approximately 6% or \$18.1 million in 2009. Changes in currency rates accounted for approximately \$6.8 of the decrease. The remainder of the decrease is due primarily to cost savings efforts as mentioned above. However, SG&A as a percentage of net sales increased to 15.0% compared to 14.2% of net sales in the same period of the prior year primarily due to lower sales volumes.

In 2008, our SG&A increased approximately 8% or \$23.0 million. Changes in currency rates accounted for approximately \$13.1 million of the increase or 5% of the 8% increase. The remaining increase is primarily due to inflationary cost increases, higher bad debt expense and higher professional fees related to several corporate initiatives. SG&A expenses as a percentage of sales remained relatively consistent with the prior year at 14.2% in 2008 compared to 14.4% in 2007.

#### **DEPRECIATION AND AMORTIZATION**

Depreciation and amortization expense increased 1% or \$1.9 million in 2009 to \$133.0 million compared to \$131.1 million in 2008. Changes in currency rates reduced depreciation and amortization expense by approximately \$5.6 million. The increase in depreciation and amortization after the change in currency rates is primarily due to the implementation of our worldwide enterprise reporting system. Depreciation and amortization expense increased to 7.2% of net sales in 2009 compared to 6.3% in 2008 mainly due to the implementation of our worldwide enterprise reporting system and the write-off of unutilized assets combined with lower sales volumes.

In 2008, depreciation and amortization expense increased 6% or \$7.7 million. Changes in currency rates accounted for approximately \$6.7 million of the increase. Depreciation and amortization expense decreased to 6.3% of net sales in 2008 compared to 6.5% in 2007.

15 /ATR

2009 Form 10-K

---

**Table of Contents**

**FACILITIES CONSOLIDATION AND SEVERANCE EXPENSE**

Facilities consolidation and severance expenses were \$7.6 million (0.4% of sales) in 2009. There were no corresponding expenses in 2008 or 2007. The amount represents the recognition of expenses related to the Company's plan to consolidate several facilities and reduce headcount. The total costs associated with the consolidation/severance programs are estimated to be approximately \$8 million. Annual savings are estimated to be in the range of \$3 million to \$4 million primarily beginning in 2010.

**OPERATING INCOME**

Operating Income decreased approximately \$35.8 million or 15% to \$198.4 million. The decrease is primarily due to the decrease in sales of our products, particularly in the Beauty & Home segment, the strengthening of the U.S. dollar compared to the Euro which is having a negative impact on the translation of our results in U.S. dollars, the increased amount of depreciation reported in 2009 and the impact of the facilities consolidation and severance program discussed above. Operating income as a percentage of sales decreased to 10.8% in 2009 compared to 11.3% in 2008 primarily for the same reasons.

In 2008, operating income increased approximately \$21.3 million or 10% to \$234.2 million. The increase in operating income is primarily due to the increase in sales of our products to the pharmaceutical market and the relative strength of the euro compared to the U.S. dollar which has an additive effect on the translation of our European results. This was partially offset by higher input and SG&A costs as mentioned above. 2008 operating income as a percentage of sales remained consistent with 2007 at 11.3%.

**NET OTHER EXPENSES**

Net other expenses in 2009 increased to \$14.3 million compared to \$7.5 million in 2008 principally reflecting the lower interest income of \$9.8 million partially offset by lower interest expense of \$2.2 million due to lower interest rates and lower external borrowings in 2009 compared to 2008.

In 2008, net other expenses decreased to \$7.5 million compared to \$10.7 million in 2007 principally reflecting the higher interest income of \$4.2 million due to higher average cash balances in 2008 compared to 2007, offset partially by higher foreign currency losses of \$1.7 million.

**EFFECTIVE TAX RATE ON INCOME FROM CONTINUING OPERATIONS**

The reported effective tax rate on income from continuing operations for 2009 and 2008 was 32.3%. The stable tax rate for 2009 includes the tax cost associated with an increase in dividend repatriation from Europe in 2009 offset by a change in the mix of income earned by country and savings from special elections available in Italy during 2009.

In 2008, the reported effective tax rate for 2008 increased to 32.3% compared to 31.0% in 2007. The increase in the tax provision for 2008 reflects primarily a change in the mix of income earned by country. This increase was partially offset by the benefits from tax changes that became effective in the current year related to lower tax rates in Germany and Italy.

**INCOME FROM CONTINUING OPERATIONS**

We reported income from continuing operations of \$124.6 million in 2009 compared to \$153.5 million reported in 2008 and \$139.5 million reported in 2007.

**INCOME FROM DISCONTINUED OPERATIONS**

In the fourth quarter of 2007, we sold our Australian operation for approximately \$6.7 million in cash and generated a gain on the sale of approximately \$3.9 million before tax or \$2.2 million after tax. Due to the immateriality of the results of the Australian operation, only the net gain of \$2.2 million is reported in the Consolidated Statements of Income in the line Income From Discontinued Operations Net of Tax.

**NET INCOME**

We reported net income of \$124.6 million in 2009 compared to \$153.5 million reported in 2008 and \$141.7 million reported in 2007.

### BEAUTY & HOME SEGMENT

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>	<b>% Change 2009 vs. 2008</b>	<b>% Change 2008 vs. 2007</b>
Net Sales	\$ <b>920,669</b>	\$ 1,072,478	\$ 1,005,218	(14.2)%	6.7%
Segment Income (1)	<b>58,844</b>	89,724	95,635	(34.4)	(6.2)
Segment Income as a percentage of Net Sales	<b>6.4%</b>	8.4%	9.5%		

(1) Segment income is defined as earnings before net interest, corporate expenses and income taxes and unusual items. The Company evaluates performance of its business units and allocates resources based upon segment income. For a reconciliation of segment income to income before income taxes, see Note 17 to the Consolidated Financial Statements in Item 8.

Net sales decreased approximately 14% in 2009 to \$920.7 million compared to \$1.1 billion in 2008. The strengthening U.S. dollar compared to the Euro negatively impacted sales and represented approximately 5% of the decrease while

16 /ATR

2009 Form 10-K

**Table of Contents**

acquisitions were immaterial. The remaining 9% of the sales decrease was due mainly to declines in our fragrance/cosmetic and household markets. Sales excluding changes in exchange rates of our products to the fragrance/cosmetic and household markets decreased approximately 15% and 3%, respectively, in 2009 due to the economic conditions felt mainly in North America and Europe. However, fragrance/cosmetic and household sales to our developing markets such as Latin America and Southeast Asia continued to grow. The overall decrease in sales to the fragrance/cosmetic market was partially offset by sales to our personal care market. Sales excluding changes in exchange rates of our products to the personal care market increased 2% in 2009 mainly due to the increase in sales of our dispensing systems used on hand sanitizers and anti-bacterial products related to increased H1N1 flu awareness. In 2008, net sales increased approximately 7% in 2008 to \$1.1 billion compared to \$1.0 billion in 2007. The weakening U.S. dollar compared to the Euro positively impacted the sales increase and represented approximately 5% of the increase while acquisitions were immaterial. The remaining 2% of the increase in sales was led by increased demand for our products from the fragrance/cosmetic market. Sales excluding changes in exchange rates of our products to the fragrance/cosmetic market increased approximately 4% in 2008 reflecting a continued growth in developing markets such as Latin America and Southeast Asia. Sales to Eastern Europe, the U.S. and parts of Western Europe were down in the second half of the year due to general economic conditions. Sales excluding changes in exchange rates of our products to the personal care and household markets were flat and down 4%, respectively, in 2008. We did not see any erosion in our customer base, but again attribute this softness to the general economic conditions.

Segment income decreased approximately 34% to \$58.8 million in 2009 compared to \$89.7 million reported in 2008. Acquisitions did not materially impact segment income during the year. The decrease in segment income of \$30.9 million is due primarily to the reduction in sales (particularly to the fragrance/cosmetic market), underutilized overhead and the negative impact of a \$1.5 million charge related to facilities consolidation and severance expenses. Although significant cost reduction activities were implemented during the year, it was not enough to offset the decline in sales volume, particularly in the first half of the year.

In 2008, segment income decreased approximately 6% to \$89.7 million in 2008 compared to \$95.6 million reported in 2007. The decrease in segment income of \$5.9 million was due primarily to the significant increase in input costs for the first nine months of the year and our inability to pass on these costs fast enough to our customers. In addition, soft general economic conditions in the fourth quarter lead to underutilized capacity at some of our operations.

**CLOSURES SEGMENT**

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>	<b>% Change 2009 vs. 2008</b>	<b>% Change 2008 vs. 2007</b>
Net Sales	\$ 490,548	\$ 541,745	\$ 493,000	(9.5)%	9.9%
Segment Income	49,769	43,934	48,217	13.3	(8.9)
Segment Income as a percentage of Net Sales	10.1%	8.1%	9.8%		

Net sales to the Closures segment decreased more than 9% in 2009 to \$490.5 million compared to \$541.7 million in 2008. The strengthening U.S. dollar compared to the Euro negatively impacted the sales decrease and represented approximately 5% of the decrease while an acquisition represented a favorable impact of 2%. Excluding changes in exchange rates and acquisitions, sales decreased 6% in 2009 compared to the same period of the prior year. Decreases in resin prices led to lower selling prices due to the pass through nature of this business and represented approximately 7% of the decline. Tooling sales excluding foreign currency and acquisitions also declined \$12.7 million compared to

the prior year. Sales excluding foreign currency changes to the personal care and household markets decreased approximately 9% and 16%, respectively, during 2009 compared to the same period in the prior year primarily due to the resin price pass through discussed above. An 8% increase in sales to the food and beverage market excluding currency changes was also adversely impacted by lower resin price pass through.

In 2008, net sales to the Closures segment increased nearly 10% in 2008 to \$541.7 million compared to \$493.0 million in 2007. The weakening U.S. dollar compared to the Euro positively impacted the sales increase and represented approximately 4% of the increase. Of the remaining 6% growth, increased selling prices due to the rising cost of resin accounted for approximately 4% of the increase while sales of custom tooling contributed 1%. 2008 also represented two dramatically different halves of business for the Closures segment. The first half of the year was positively impacted by favorable exchange rates (mainly Euro), a higher resin pass through, and higher tooling sales.

Conversely, the second half of 2008 saw an unfavorable exchange rate impact (Euro, Mexican Peso, and Brazilian Real) and lower tooling sales, primarily in Europe. For the full year, sales excluding changes in exchange rates of our products to the food market increased 19% in 2008 mainly due to new ketchup and salad dressing launches in the U.S. This increase was offset by a 15% decrease in the household market during 2008 reflecting the loss of a detergent cap customer as well as a general slowdown in the closure personal care market.

Segment income increased 13% to \$49.8 million in 2009 compared to \$43.9 million in 2008. Included in these results are approximately \$5.7 million of consolidation/restructuring expenses. The increase in segment income is primarily due to cost savings activities, the continued growth of the food/beverage market and the normal delay in the pass-through of lower resin costs to our customers during 2009.

17 /ATR

2009 Form 10-K

---

**Table of Contents**

In 2008, segment income decreased 9% to \$43.9 million in 2008 compared to \$48.2 million in 2007. As was the case with the Beauty and Home segment, rising input costs during the first nine months of the year and our inability to pass these increased costs on to customers fast enough coupled with underutilized fixed overhead costs, particularly in Europe, were the primary reasons for the decrease in profitability.

**PHARMA SEGMENT**

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>	<b>% Change 2009 vs. 2008</b>	<b>% Change 2008 vs. 2007</b>
Net Sales	\$ <b>430,397</b>	\$ 457,456	\$ 393,868	(5.9)%	16.1%
Segment Income	<b>123,654</b>	129,591	105,974	(4.6)	22.3
Segment Income as a percentage of Net Sales	<b>28.7%</b>	28.3%	26.9%		

Net sales to the Pharma segment decreased by nearly 6% in 2009 to \$430.4 million compared to \$457.5 million in 2008. The strengthening U.S. dollar compared to the Euro negatively impacted the sales decrease and represented approximately 4% of the decrease while acquisitions were immaterial. The remaining 2% decline is due to softer demand for both metered dose inhaler valves ( MDI s ) and nasal spray pumps sold to the export markets.

In 2008, net sales to the Pharma segment increased more than 16% in 2008 to \$457.5 million compared to \$393.9 million in 2007. Changes in foreign currency rates positively affected the sales growth and accounted for 6% of the total growth. The remaining increase is primarily related to increased demand for our MDI s used to dispense asthma medications and nasal spray pumps used to dispense allergy medications.

Segment income decreased 5% to \$123.7 million in 2009 compared to \$129.6 million reported in 2008. The decrease in profit is primarily due to lower sales and the impact of changes in currency exchange rates. Also included in segment income were \$433 thousand related to the consolidation/restructure expenses.

In 2008, segment income increased 22% to \$129.6 million compared to \$106.0 million reported in 2007. The increase in segment income is primarily due to the higher sales volumes detailed above.

**LIQUIDITY AND CAPITAL RESOURCES**

Our primary sources of liquidity are cash flow provided by our operations and our revolving credit facility. Cash and equivalents increased to \$333.0 million at the end of 2009 from \$192.1 million at the end of 2008. Total short and long-term interest bearing debt increased to \$338.0 million at the end of 2009 from \$291.5 million at the end of 2008. The ratio of our Net Debt (interest bearing debt less cash and cash equivalents) to Net Capital (Stockholders' Equity plus Net Debt) decreased to 0.4% compared to 8.1% as of December 31, 2008.

In 2009, our operations provided a record \$293.6 million in cash flow. This compares with \$270.2 million in 2008 and \$273.5 million in 2007. In 2009, the lower net income and higher pension contributions were more than offset by a reduction in working capital. In 2008 and 2007, we primarily derived cash flow from operations from earnings before depreciation and amortization partially offset by an increase in working capital needs to support the growth of the business. During 2009, we utilized the majority of the operating cash flows to finance capital expenditures and share repurchases.

We used \$151.1 million in cash for investing activities during 2009, compared to \$225.5 million during 2008 and \$131.2 million in 2007. This decrease in cash used for investing activities in 2009 is primarily due to decreased capital expenditures compared to the prior year and \$12 million less cash spent for acquisitions of businesses in 2009

compared to 2008. Capital expenditures totaled \$144.9 million in 2009, \$203.6 million in 2008 and \$137.9 million in 2007. Each year we invest in property, plant and equipment primarily for new products, capacity increases, product line extensions and maintenance of business. We estimate that we will spend approximately \$125 million (assuming current exchange rates) on capital expenditures in 2010.

We used \$13.2 million in cash for financing activities during 2009 compared to \$151.6 million in 2008 and \$22.9 million in 2007. We refinanced some of our short term variable rate debt with a \$100 million fixed rate private placement debt in the third quarter of 2008. \$25 million of the private placement debt has a five year maturity and a fixed interest rate of 5.41% while the remaining \$75 million matures in ten years and carries a 6.03% fixed interest rate. In the fourth quarter of 2008, we borrowed \$100 million on an intercompany loan basis from one of our European affiliates, taking advantage of certain temporary U.S. tax law changes which enabled us to borrow the money on a short term basis without adverse U.S. tax consequences. This \$100 million was used to pay down borrowings under our revolving credit facility in 2008 and the intercompany loan was retired in 2009 primarily by funds repatriated from the dividend from Europe.

In 2006, we negotiated an amendment to our revolving credit facility (including a \$50 million increase in the amount of the facility to \$200 million). Under our credit agreement, interest on borrowings is payable at a rate equal to LIBOR plus an amount based on our financial condition. We are required to pay a nominal fee for this commitment based on our financial condition. The agreement expires on July 31, 2012. The Company can also request a \$100 million increase in the total amount of the facility. At December 31, 2009, the amount unused and available under this agreement was \$100 million.

18 /ATR

2009 Form 10-K

---

**Table of Contents**

Our revolving credit facility and certain long-term obligations require us to satisfy certain financial and other covenants including:

	<b>Requirement</b>	<b>Level at December 31, 2009</b>
Debt to total capital ratio	55%	21%

Based upon the above debt to total capital ratio covenant we would have the ability to borrow approximately an additional \$1.2 billion before the 55% requirement was exceeded.

Our foreign operations have historically met cash requirements with the use of internally generated cash or borrowings. These foreign subsidiaries have financing arrangements with several foreign banks to fund operations located outside the U.S., but all these lines are uncommitted. Cash generated by foreign operations has generally been reinvested locally. The majority of our \$333.0 million in cash and equivalents is located outside of the U.S.

We believe we are in a strong financial position and have the financial resources to meet business requirements in the foreseeable future. We have historically used cash flow from operations as our primary source of liquidity. In the event that customer demand would decrease significantly for a prolonged period of time and negatively impact cash flow from operations, we would have the ability to restrict and significantly reduce capital expenditure levels, which historically have been the most significant use of cash for us. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

**OFF-BALANCE SHEET ARRANGEMENTS**

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating leases expiring at various dates through the year 2029. Most of the operating leases contain renewal options and certain equipment leases include options to purchase during or at the end of the lease term. Other than operating lease obligations, we do not have any off-balance sheet arrangements. See the following section **Overview of Contractual Obligations** for future payments relating to operating leases.

**OVERVIEW OF CONTRACTUAL OBLIGATIONS**

Below is a table of our outstanding contractual obligations and future payments as of December 31, 2009:

<b>Payment Due by Period</b>	<b>Total</b>	<b>2010</b>	<b>2011-2012</b>	<b>2013-2014</b>	<b>2015 and After</b>
Long-term debt (1)	\$ 229,124	\$ 24,476	\$ 50,767	\$ 28,862	\$ 125,019
Capital lease obligations (1)	5,607	639	1,716	804	2,448
Operating leases	44,530	14,273	17,037	4,496	8,724
Interest obligations (2)	72,480	13,980	20,121	16,364	22,015
Required minimum pension contribution (3)					
Other liabilities reflected on the balance sheet under GAAP (4)	34	34			



Total Contractual Obligations	\$	351,775	\$	53,402	\$	89,641	\$	50,526	\$	158,206
-------------------------------	----	---------	----	--------	----	--------	----	--------	----	---------

- (1) The future payments listed above for capital lease obligations and long-term debt repayments reflect only principal payments.
- (2) Approximately 36% of our total interest bearing debt has variable interest rates. Using our variable rate debt outstanding as of December 31, 2009 of approximately \$121.2 million at an average rate of approximately 1.2%, we included approximately \$1.5 million of variable interest rate obligations in 2010. No variable interest rate obligations were included in subsequent years.
- (3) Line represents the required minimum pension contribution obligation for the Company's U.S. plans. At this time, the Company is not required to make a contribution. The Company also makes contributions to its foreign pension plans but amounts are expected to be discretionary in 2010 and future years. Therefore amounts related to these plans are not included in the preceding table.
- (4) Amount included represents the current portion of the liability for uncertain tax positions. Aside from deferred income taxes and minority interest, we have approximately \$54.6 million of other deferred long-term liabilities on the balance sheet, which consist primarily of retirement plan obligations as described in Note 9 to the Consolidated Financial Statements and a long-term liability for uncertain tax positions described in Note 6 to the Consolidated Financial Statements. The Company is not able to reasonably estimate the timing of the long-term payments or the amount by which the liability will increase or decrease over time. Therefore, the long-term portion of the liability is excluded from the preceding table.

19 /ATR

2009 Form 10-K

**Table of Contents****ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS**

The Financial Accounting Standards Board (FASB) issued a new standard establishing the FASB Accounting Standards Codification<sup>™</sup> (Codification) as the single source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. The issuance of this standard and the Codification does not change GAAP. We have adopted this standard for the current reporting period.

In October 2009, the FASB issued an update to existing guidance on revenue recognition for arrangements with multiple deliverables. This update will allow companies to allocate consideration received for qualified separate deliverables using estimated selling price for both delivered and undelivered items when vendor-specific objective evidence or third-party evidence is unavailable. Additional disclosures discussing the nature of multiple element arrangements, the types of deliverables under the arrangements, the general timing of their delivery, and significant factors and estimates used to determine estimated selling prices are required. The standard is effective for fiscal years beginning on or after June 15, 2010. We are currently evaluating the potential impact of this new standard but do not believe it will have a material impact on our financial statements.

In August 2009, the FASB further updated the fair value measurement guidance to clarify how an entity should measure liabilities at fair value. The update reaffirms fair value is based on an orderly transaction between market participants, even though liabilities are infrequently transferred due to contractual or other legal restrictions. However, identical liabilities traded in the active market should be used when available. When quoted prices are not available, the quoted price of the identical liability traded as an asset, quoted prices for similar liabilities or similar liabilities traded as an asset, or another valuation approach should be used. This update also clarifies that restrictions preventing the transfer of a liability should not be considered as a separate input or adjustment in the measurement of fair value. The guidance provided in this update is effective for the first reporting period beginning after issuance. Therefore, we have adopted this standard for the current reporting period.

In June 2009, the FASB issued a new accounting standard which provides amendments to previous guidance on the consolidation of variable interest entities. This standard clarifies the characteristics that identify a variable interest entity ( VIE ) and changes how a reporting entity identifies a primary beneficiary that would consolidate the VIE from a quantitative risk and rewards calculation to a qualitative approach based on which variable interest holder has controlling financial interest and the ability to direct the most significant activities that impact the VIE s economic performance. This statement requires the primary beneficiary assessment to be performed on a continuous basis. It also requires additional disclosures about an entity s involvement with a VIE, restrictions on the VIE s assets and liabilities that are included in the reporting entity s consolidated balance sheet, significant risk exposures due to the entity s involvement with the VIE, and how its involvement with a VIE impacts the reporting entity s consolidated financial statements. The standard is effective for fiscal years beginning after November 15, 2009. We are currently evaluating the potential impact of this new standard but do not believe it will have a material impact on our financial statements.

In December 2008, the FASB issued an update to accounting standards related to an employer s disclosures about postretirement benefit plan assets. This update amends the disclosure requirements for employer s disclosure of plan assets for defined benefit pensions and other postretirement plans. The objective of this update is to provide users of financial statements with an understanding of how investment allocation decisions are made, the major categories of plan assets held by the plans, the inputs and valuation techniques used to measure the fair value of plan assets, significant concentration of risk within the company s plan assets, and for fair value measurements determined using significant unobservable inputs a reconciliation of changes between the beginning and ending balances. The update is effective for fiscal years ending after December 15, 2009. Therefore, we have adopted the new disclosure

requirements in this reporting period.

In April 2008, the FASB issued an update to the accounting standards related to determination of the useful life of intangible assets. This update amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under previous standards in order to improve the consistency between the useful life of a recognized intangible asset and the period of expected cash flows used to measure the fair value of the asset and other GAAP. This update is effective on January 1, 2009. The adoption did not have a material impact on our financial statements.

In March 2008, the FASB issued an update to disclosures about derivative instruments and hedging activities. This update requires enhanced disclosures about an entity's derivative and hedging activities, including (i) how and why an entity uses derivative instruments, (ii) how derivative instruments and related hedged items are accounted for, and (iii) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. This standard is effective on January 1, 2009. As this update only required enhanced disclosures, this standard did not have an impact on the financial position, results of operations, or cash flows of the Company.

#### CRITICAL ACCOUNTING ESTIMATES

The preparation of the financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate

20 /ATR

2009 Form 10-K

---

**Table of Contents**

our estimates, including those related to bad debts, inventories, intangible assets, income taxes, pensions and contingencies. We base our estimates on historical experience and on a variety of other assumptions believed to be reasonable in order to make judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in preparation of our Consolidated Financial Statements. Management has discussed the development and selection of these critical accounting estimates with the audit committee of our Board of Directors and the audit committee has reviewed our disclosure relating to it in this Management's Discussion and Analysis of Consolidated Results of Operations and Financial Condition ( MD&A ).

**IMPAIRMENT OF GOODWILL**

In accordance with current accounting standards, we evaluate our goodwill for impairment on an annual basis, or whenever indicators of impairment exist. Due to the economic uncertainty in 2009, we evaluated our goodwill for triggering events at the end of each quarter noting no indicators that a full impairment assessment was necessary. Accounting standards require that if the carrying value of a reporting unit for which goodwill exists exceeds its fair value, an impairment loss is recognized to the extent that the carrying value of the reporting unit goodwill exceeds the implied fair value of reporting unit goodwill.

As discussed in Note 4 to the Consolidated Financial Statements, we have evaluated our goodwill for impairment and have determined that the fair value of our reporting units exceeds their carrying value, so we did not recognize an impairment of goodwill. Goodwill of approximately \$230.6 million is shown on our balance sheet as of December 31, 2009.

We believe that the accounting estimate related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires company management to make assumptions about the future cash flows for each reporting unit over several years in the future, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management's assumptions about future cash flows for the reporting units require significant judgment and actual cash flows in the future may differ significantly from those forecasted today. The estimate for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate for all the segments of our business.

In estimating future cash flows, we use internally generated budgets developed from our reporting units and reviewed by management. We develop our budgets based upon recent sales trends for the reporting units, discussions with our customers, planned timing of new product launches, forecasted capital expenditure needs, working capital needs, costing factors and many other variables. From these internally generated budgets, a projection of cash flows is made based upon expected sales growth rates and fixed asset and working capital requirements based upon historical needs. Starting with our 2010 budget figures we have used sales growth rates of 5% for all three reporting segments. We have assumed that operating income will grow by 8% for both the Beauty and Home and Closures reporting segments while the Pharma segment operating income growth rate used was the same as the sales growth rate. Capital expenditures, working capital needs, and taxes and depreciation are based on historical trends and what is necessary to support the business in the future. We forecast our cash flows for 4 years and use a terminal value growth rate of 3%. These assumptions have not changed significantly from the prior year. A discounted cash flow model is used to discount the future cash flows back to the present using a weighted-average cost of capital. Our weighted average cost of capital calculation takes into consideration market risk premiums in the current equity and debt markets supplied by third party sources. We perform one calculation using our current debt to equity ratio. Due to our strong balance sheet and low debt levels, the weighted average cost of capital calculation using our current debt to equity ratio is 8.7%, which is a higher discount rate than if we used our targeted debt to equity ratio. We have used the same weighted average cost of capital for all our reporting segments. This fair value for the reporting unit is then corroborated by comparing it with a market multiple analysis of the reporting unit. The market multiple analysis is calculated by using AptarGroup's overall EBITDA (earnings before interest, taxes and depreciation) multiple and applying it to the reporting unit EBITDA for the current year.

The \$230.6 million of goodwill is reported in three reporting units. Approximately \$28.4 million of the goodwill is allocated to the Pharma reporting segment, \$161.8 million is allocated to the Beauty and Home reporting segment and \$40.3 million is allocated to the Closures reporting segment. Two of the three reporting units have fair values, which significantly exceed their carrying values. The third reporting unit contains approximately \$40.3 million of the total \$230.6 million in goodwill and has the smallest excess of fair value over carrying value of the three reporting units. We believe our assumptions used in discounting future cash flows are appropriately conservative. Any increase in estimated cash flows would have no impact on the reported carrying amount of goodwill. However, if our current estimates of cash flow for this one reporting unit had been 69% lower, the fair value of the reporting unit would have been lower than the carrying value thus requiring us to perform an impairment test to determine the implied value of goodwill. The excess of the approximately \$40.3 million in carrying value of goodwill over the implied value of goodwill would need to be written down for impairment. Without performing the second step of the goodwill impairment test, it would be difficult to determine the actual amount of impairment to be recorded, but theoretically, the full \$40.3 million of goodwill would be at risk for impairment. A full \$40.3 million impairment loss would have reduced Total Assets as of December 31, 2009 by approximately 2% and would have reduced Income From Continuing Operations Before Income Taxes in 2009 by approximately 22%. If we had been required to recognize an impairment loss of the full \$40.3 million, it would likely not have affected our liquidity and capital resources because, in spite of the impairment loss, we would have been within the terms of our debt covenants.

21 /ATR

2009 Form 10-K

---

**Table of Contents****ALLOWANCE FOR DOUBTFUL ACCOUNTS**

We record an allowance for doubtful accounts as an estimate of the inability of our customers to make their required payments. We determine the amount of our allowance for doubtful accounts by looking at a variety of factors. First, we examine an aging of the accounts receivable in each entity within the Company. The aging lists past due amounts according to invoice terms. In addition, we consider the current economic environment, the credit rating of the customers and general overall market conditions. In some countries we maintain credit insurance, which can be used in certain cases of non-payment.

We believe that the accounting estimate related to the allowance for doubtful accounts is a critical accounting estimate because: (1) it requires management to make assumptions about the ability to collect amounts owed from customers in the future, and (2) changes to these assumptions or estimates could have a material impact on our results of operations. The estimate for the allowance for doubtful accounts is a critical accounting estimate for all of our segments.

When we determine that a customer is unlikely to pay, we record a charge to bad debt expense in the income statement and an increase to the allowance for doubtful accounts. When it becomes certain the customer cannot pay (typically driven by the customer filing for bankruptcy) we write off the receivable by removing the accounts receivable amount and reducing the allowance for doubtful accounts accordingly. In 2009, we added approximately \$0.7 million to the allowance for doubtful accounts while we wrote off or reduced the allowance for doubtful accounts by \$2.7 million. Please refer to Schedule II Valuation and Qualifying Accounts for activity in the allowance for doubtful accounts over the past three years.

We had approximately \$319.8 million in net accounts receivable at December 31, 2009. At December 31, 2009, we had approximately \$9.9 million recorded in the allowance for doubtful accounts to cover all potential future customer non-payments net of any credit insurance reimbursement we would potentially recover. We believe our allowance for doubtful accounts is adequate to cover any future non-payments of our customers. However, if economic conditions deteriorate significantly or one of our large customers was to declare bankruptcy, a larger allowance for doubtful accounts might be necessary. It is extremely difficult to estimate how much of an additional reserve would be necessary, but we expect the largest potential customer balance at any one time would not exceed \$18.0 million. An additional loss of \$18.0 million would reduce our Total Assets as of December 31, 2009 by approximately 1% and would have reduced Income From Continuing Operations Before Income Taxes by approximately 10%.

If we had been required to recognize an additional \$18.0 million in bad debt expense, it would likely not have significantly affected our liquidity and capital resources because, in spite of the additional expense, we would have been within the terms of our debt covenants.

**VALUATION OF PENSION BENEFITS**

The benefit obligations and net periodic pension cost associated with our domestic and foreign noncontributory pension plans are determined using actuarial assumptions. Such assumptions include discount rates to reflect the time value of money, rate of employee compensation increases, demographic assumptions to determine the probability and timing of benefit payments, and the long-term rate of return on plan assets. The actuarial assumptions are based upon management's best estimates, after consulting with outside investment advisors and actuaries. Because assumptions and estimates are used, actual results could differ from expected results.

The discount rate is utilized principally in calculating our pension obligations, which are represented by the Accumulated Benefit Obligation (ABO) and the Projected Benefit Obligation (PBO), and in calculating net periodic benefit cost. In establishing the discount rate for our foreign plans, we review a number of relevant interest rates including government security yields and Aa corporate bond yields. In establishing the discount rate for our domestic plans, we match the hypothetical duration of our plans, using a weighted average duration that is based upon projected cash payments, to a simulated bond portfolio (Citigroup Pension Index Curve). At December 31, 2009, the discount rates for our domestic and foreign plans were 5.90% and 5.55%, respectively.

We believe that the accounting estimates related to determining the valuation of pension benefits are critical accounting estimates because: (1) changes in them can materially affect net income, and (2) we are required to establish the discount rate and the expected return on fund assets, which are highly uncertain and require judgment. The estimates for the valuation of pension benefits are critical accounting estimates for all of our segments.

To the extent the discount rates increase (or decrease), our PBO and net periodic benefit cost will decrease (or increase) accordingly. The estimated effect of a 1% decrease in each discount rate would be a \$19.8 million increase in the PBO (\$14.1 million for the domestic plans and \$5.7 million for the foreign plans) and a \$2.6 million increase in net periodic benefit cost (\$2.1 million for the domestic plans and \$0.5 million for the foreign plans). To the extent the PBO increases, the after-tax effect of such increase could reduce Other Comprehensive Income and Stockholders Equity. The estimated effect of a 1% increase in each discount rate would be a \$15.9 million decrease in the PBO (\$11.2 million for the domestic plans and \$4.7 million for the foreign plans) and a \$1.4 million decrease in net periodic benefit cost (\$1 million for the domestic plans and \$0.4 million for the foreign plans). A decrease of this magnitude in the PBO would eliminate a substantial portion of the related reduction in Other Comprehensive Income and Stockholders Equity.

The assumed expected long-term rate of return on assets is the average rate of earnings expected on the funds invested to provide for the benefits included in the PBO. Of domestic plan assets, approximately 55% was invested in equities, 35% was invested in fixed income securities, 9% was invested in infrastructure and 1% was invested in a money market fund at December 31, 2009. Of foreign plan assets, approximately 17% was invested in equities, 32% was invested in fixed income securities, 4% was invested in real estate and 47% was invested in a money market fund at December 31, 2009. The Company

22 /ATR

2009 Form 10-K

---

**Table of Contents**

contributed approximately \$15.0 million in December 2009 to partially fund its previously unfunded German pension plans. These funds were invested in money market funds at December 31, 2009 and will be reinvested according to the foreign plan target allocation in 2010.

The expected long-term rate of return assumptions are determined based on our investment policy combined with expected risk premiums of equities and fixed income securities over the underlying risk-free rate. This rate is utilized principally in calculating the expected return on the plan assets component of the net periodic benefit cost. To the extent the actual rate of return on assets realized over the course of a year is greater or less than the assumed rate, that year's net periodic benefit cost is not affected. Rather, this gain (or loss) reduces (or increases) future net periodic benefit cost over a period of approximately 15 to 20 years. To the extent the expected long-term rate of return on assets increases (or decreases), our net periodic benefit cost will decrease (or increase) accordingly. The estimated effect of a 1% decrease (or increase) in each expected long-term rate of return on assets would be a \$0.5 million increase (or decrease) in net periodic benefit cost.

The average rate of compensation increase is utilized principally in calculating the PBO and the net periodic benefit cost. The estimated effect of a 0.5% decrease in each rate of expected compensation increase would be a \$2.4 million decrease in the PBO (\$0.8 million for the domestic plans and \$1.6 million for the foreign plans) and a \$0.5 million decrease to the net periodic benefit cost. The estimated effect of a 0.5% increase in each rate of expected compensation increase would be a \$2.5 million increase in the PBO (\$0.8 million for the domestic plans and \$1.7 million for the foreign plans) and a \$0.4 million increase to the net periodic benefit cost.

Our primary pension related assumptions as of December 31, 2009 and 2008 were as follows:

<b>Actuarial Assumptions as of December 31,</b>	<b>2009</b>	<b>2008</b>
Discount rate:		
Domestic plans	<b>5.90%</b>	6.00%
Foreign plans	<b>5.55%</b>	5.60%
Expected long-term rate of return on plan assets:		
Domestic plans	<b>7.00%</b>	7.00%
Foreign plans	<b>4.55%</b>	6.00%
Rate of compensation increase:		
Domestic plans	<b>4.00%</b>	4.00%
Foreign plans	<b>3.00%</b>	3.00%

In order to determine the 2010 net periodic benefit cost, the Company expects to use the December 31, 2009 discount rates, rates of compensation increase assumptions and expected long-term returns on domestic and foreign plan assets. The estimated impact of the changes to the assumptions as noted in the table above on our 2010 net periodic benefit cost is not expected to be significant.



**Table of Contents**

**SHARE-BASED COMPENSATION**

The Company uses the Black-Scholes option-valuation model to value stock options, which requires the input of subjective assumptions. These assumptions include the length of time employees will retain their vested stock options before exercising them ( expected term ), the estimated volatility of the Company s stock price, risk-free interest rate, the expected dividend yield and stock price. The expected term of the options is based on historical experience of similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. The expected term determines the period for which the risk-free interest rate and volatility must be applied. The risk-free interest rate is based on the expected U.S. Treasury rate over the expected term. Expected stock price volatility is based on historical volatility of the Company s stock price. Dividend yield is management s long-term estimate of annual dividends to be paid as a percentage of share price.

For 2009, expense related to share-based compensation was \$9.8 million and represented approximately \$0.10 per diluted share. Future changes in the subjective assumptions used in the Black-Scholes option-valuation model or estimates associated with forfeitures could impact our share-based compensation expense. For example, a 1 year reduction in the expected term of the options would decrease the Black-Scholes valuation and reduce share-based compensation by approximately \$0.4 million. On the contrary, a 1 year increase in the expected term of the option would increase the Black-Scholes valuation and increase share-based compensation by approximately \$0.3 million. In addition, changes in the stock price at the date of the grant would impact our share-based compensation expense. For example, a \$5 decrease in the stock price would decrease the Black-Scholes valuation and reduce share-based compensation by approximately \$1.0 million. On the contrary, a \$5 increase in the stock price would increase the Black-Scholes valuation and increase share-based compensation by approximately \$0.9 million.

**OPERATIONS OUTLOOK**

While we are encouraged by our fourth quarter results, the current economic uncertainty has not ended. The difficult unemployment situation in the U.S. and the generally sluggish economies in Europe will take some time to rebound. The first quarter 2010 results are expected to show improvement compared to the prior year. Preliminary indications are that consumer confidence, primarily in the U.S. and Europe, will continue to rise and demand for our personal care and fragrance/cosmetic dispensing systems will be above prior year levels. Demand for our food and beverage dispensing systems will be driven by the continued conversion away from non-dispensing packaging. In addition, we expect stable demand for our unique drug delivery solutions and services from the pharmaceutical market.

The U.S. dollar has recently strengthened compared to the Euro and other currencies but is still weaker than what we experienced in the first quarter of 2009. Since a majority of our sales are denominated in Euros, a weaker dollar will have an additive impact on the translation of our Euro denominated financial statements into U.S. dollars. However, as we have mentioned before, we are a net importer of products produced in European countries with Euro based costs into the U.S. and sold in U.S. dollars. A weakened U.S. dollar compared to the Euro makes imported European produced products more expensive, thereby reducing operating margins. The net impact of the weakened U.S. dollar is difficult to predict or estimate, but it is likely that any positive impact realized from translating Euro denominated financial statements into U.S. dollars would be partially offset by the higher cost of imported products.

We expect the annual effective tax rate for 2010 to be in the range of 32.0% to 33.0% compared to a rate of 32.3% for 2009.

We are anticipating diluted earnings per share for the first quarter of 2010 to be in the range of \$.48 to \$.53 per share compared to \$.38 per share recorded in the first quarter of 2009.

24 /ATR

2009 Form 10-K

**Table of Contents**

**FORWARD-LOOKING STATEMENTS**

This Management's Discussion and Analysis and certain other sections of this Form 10-K contain forward-looking statements that involve a number of risks and uncertainties. Words such as expects, anticipates, believes, estimates, and other similar expressions or future or conditional verbs such as will, should, would and could are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment, including but not limited to:

- economic, environmental and political conditions worldwide;
- changes in customer and/or consumer spending levels;
- the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;
- the cost of materials and other input costs (particularly resin, metal, anodization costs and transportation and energy costs);
- significant fluctuations in foreign currency exchange rates;
- our ability to increase prices;
- our ability to contain costs and improve productivity;
- changes in capital availability or cost, including interest rate fluctuations;
- our ability to meet future cash flow estimates to support our goodwill impairment testing;
- direct or indirect consequences of acts of war or terrorism;
- difficulties in complying with government regulation;
- competition, including technological advances;
- our ability to protect and defend our intellectual property rights;
- the timing and magnitude of capital expenditures;
- our ability to identify potential new acquisitions and to successfully acquire and integrate such operations or products;
- work stoppages due to labor disputes;
- the demand for existing and new products;
- fiscal and monetary policy, including changes in worldwide tax rates;
- our ability to manage worldwide customer launches of complex technical products, in particular in developing markets;
- the success of our customers' products, particularly in the pharmaceutical industry;
- difficulties in product development and uncertainties related to the timing or outcome of product development;
- significant product liability claims;
- our successful implementation of a new worldwide ERP system starting in 2009 without disruption to our operations;
- our ability to implement the strategic realignment of our businesses during 2010, and
- other risks associated with our operations.

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Please refer to Item 1A ( Risk Factors ) of Part I included in the Company's Annual Report on Form 10-K for additional risk factors affecting the Company.



**Table of Contents****ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK****MARKET RISKS**

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our entities. Our primary foreign exchange exposure is to the Euro, but we also have foreign exchange exposure to the British Pound, South American and Asian currencies, among others. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect.

Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.

We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain firm purchase and sales commitments and intercompany cash transactions denominated in foreign currencies.

The table below provides information, as of December 31, 2009, about our forward currency exchange contracts. The majority of the contracts expire before the end of the first quarter of 2010 with the exception of a few contracts on intercompany loans that expire in the third quarter of 2012.

**In thousands**

<b>Year Ended December 31, 2009</b>		<b>Contract</b>	<b>Average</b>	<b>Min/Max</b>
<b>Buy/Sell</b>		<b>Amount</b>	<b>Exchange</b>	<b>Notional</b>
			<b>Rate</b>	<b>Volumes</b>
Swiss Franc/Euro	\$	45,008	0.6626	\$ 37,666-60,051
Euro/U.S. Dollar		10,163	1.4544	9,594-127,391
British Pound/Euro		8,457	1.1259	41-8,457
Czech Koruna/Euro		6,917	0.0385	1,824-6,917
Euro/Swiss Franc		5,752	1.5062	314-17,222
Euro/Brazilian Real		5,652	4.7538	5,652-6,132
Euro/Chinese Yuan		1,868	9.8824	527-1,868
U.S. Dollar/Euro		1,200	0.6964	1,200-11,146
Other		4,891		
<b>Total</b>	\$	<b>89,908</b>		

As of December 31, 2009, the Company has recorded the fair value of foreign currency forward exchange contracts of \$1.2 million in accounts payable and accrued liabilities, \$902 thousand in prepayments and other and \$2.5 million in deferred and other non-current liabilities in the balance sheet.

At December 31, 2009, we had a fixed-to-variable interest rate swap agreement with a notional principal value of \$10 million, which requires us to pay a variable interest rate (which was 0.4% at December 31, 2009) and receive a fixed rate of 6.6%. The variable rate is adjusted semiannually based on London Interbank Offered Rates ( LIBOR ). Variations in market interest rates would produce changes in our net income. If interest rates increase by 100 basis points, net income related to the interest rate swap agreement would decrease by less than \$0.1 million, assuming a tax

rate of 32%. As of December 31, 2009, we recorded the fair value of the fixed-to-variable interest rate swap agreement of \$0.6 million in miscellaneous other assets with an offsetting adjustment to debt. No gain or loss was recorded in the income statement in 2009 as any hedge ineffectiveness for the period is minimal.

As of December 31, 2009, the Company had one foreign currency cash flow hedge. A French subsidiary of AptarGroup, AptarGroup Holding SAS, has hedged the risk of variability in Euro equivalent associated with the cash flows of an intercompany loan granted in Brazilian Real. The forward contracts utilized were designated as a hedge of the changes in the cash flows relating to the changes in foreign currency rates relating to the loan and related forecasted interest. The notional amount of the foreign currency forward contracts utilized to hedge cash flow exposure was 4.2 million Brazilian Real (\$2.4 million) as of December 31, 2009. The notional amount of the foreign currency forward contracts utilized to hedge cash flow exposure was 5.5 million Brazilian Real (\$2.4 million) as of December 31, 2008. During the year ended December 31, 2009, the Company did not recognize any net gain (loss) as any hedge ineffectiveness for the period was immaterial, and the Company did not recognize any net gain (loss) related to the portion of the hedging instrument excluded from the assessment of hedge effectiveness. These foreign currency forward contracts hedge forecasted transactions for approximately two years (March 2012).

26 /ATR

2009 Form 10-K

---

Table of Contents**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

**AptarGroup, Inc.**  
**CONSOLIDATED STATEMENTS OF INCOME**

**In thousands, except per share amounts**

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>
Net Sales	\$ <b>1,841,616</b>	\$ 2,071,685	\$ 1,892,167
Operating Expenses:			
Cost of sales (exclusive of depreciation shown below)	<b>1,225,670</b>	1,411,275	1,283,773
Selling, research & development and administrative	<b>276,989</b>	295,094	272,077
Depreciation and amortization	<b>133,013</b>	131,145	123,466
Facilities consolidation and severance	<b>7,563</b>		
	<b>1,643,235</b>	1,837,514	1,679,316
Operating Income	<b>198,381</b>	234,171	212,851
Other Income (Expense):			
Interest expense	<b>(16,485)</b>	(18,687)	(19,492)
Interest income	<b>3,333</b>	13,120	8,918
Equity in results of affiliates	<b>164</b>	310	483
Miscellaneous, net	<b>(1,335)</b>	(2,188)	(679)
	<b>(14,323)</b>	(7,445)	(10,770)
Income from Continuing Operations Before Income Taxes	<b>184,058</b>	226,726	202,081
Provision For Income Taxes	<b>59,461</b>	73,225	62,607
Income From Continuing Operations	<b>124,597</b>	153,501	139,474
Income From Discontinued Operations Net of Tax			2,232
Net Income	\$ <b>124,597</b>	\$ 153,501	\$ 141,706
Net Loss (Income) Attributable to Noncontrolling interests	<b>26</b>	(6)	33
Net Income Attributable to AptarGroup, Inc.	\$ <b>124,623</b>	\$ 153,495	\$ 141,739
Net Income Per Common Share (Basic):			
Continuing Operations	\$ <b>1.84</b>	\$ 2.26	\$ 2.03

Edgar Filing: APTARGROUP INC - Form 10-K

Discontinued Operations	\$		\$		\$	0.03
Net Income Per Common Share (Basic)	\$	<b>1.84</b>	\$	2.26	\$	2.06
Net Income Per Common Share (Diluted):						
Continuing Operations	\$	<b>1.79</b>	\$	2.18	\$	1.95
Discontinued Operations	\$		\$		\$	0.03
Net Income Per Common Share (Diluted)	\$	<b>1.79</b>	\$	2.18	\$	1.98

See accompanying notes to consolidated financial statements.

27 /ATR

2009 Form 10-K

---

**Table of Contents**

**AptarGroup, Inc.**  
**CONSOLIDATED BALANCE SHEETS**

**In thousands, except per share amounts**

<b>December 31,</b>	<b>2009</b>	<b>2008</b>
<b>Assets</b>		
Current Assets:		
Cash and equivalents	\$ 332,964	\$ 192,072
Accounts and notes receivable, less allowance for doubtful accounts of \$9,923 in 2009 and \$11,900 in 2008	319,787	343,937
Inventories	230,807	244,775
Prepayments and other	59,933	78,965
	<b>943,491</b>	<b>859,749</b>
Property, Plant and Equipment:		
Buildings and improvements	322,498	297,093
Machinery and equipment	1,612,945	1,484,353
	<b>1,935,443</b>	<b>1,781,446</b>
Less: Accumulated depreciation	<b>(1,190,576)</b>	<b>(1,078,063)</b>
	<b>744,867</b>	<b>703,383</b>
Land	19,201	17,499
	<b>764,068</b>	<b>720,882</b>
Other Assets:		
Investments in affiliates	898	712
Goodwill	230,578	227,041
Intangible assets	9,088	14,061
Miscellaneous	8,070	9,377
	<b>248,634</b>	<b>251,191</b>
Total Assets	\$ 1,956,193	\$ 1,831,822

See accompanying notes to consolidated financial statements.

28 /ATR

2009 Form 10-K



**Table of Contents**

**AptarGroup, Inc.**  
**CONSOLIDATED BALANCE SHEETS**

**In thousands, except per share amounts**

<b>December 31,</b>	<b>2009</b>	<b>2008</b>
<b>Liabilities and Stockholders Equity</b>		
Current Liabilities:		
Notes payable	\$ 103,240	\$ 39,919
Current maturities of long-term obligations	25,115	24,700
Accounts payable and accrued liabilities	288,960	310,408
	<b>417,315</b>	375,027
 Long-Term Obligations	 <b>209,616</b>	 226,888
 Deferred Liabilities and Other:		
Deferred income taxes	20,992	24,561
Retirement and deferred compensation plans	40,462	62,476
Deferred and other non-current liabilities	14,172	11,072
Commitments and contingencies		
	<b>75,626</b>	98,109
 Stockholders Equity:		
AptarGroup, Inc. stockholders equity		
Preferred stock, \$.01 par value, 1 million shares authorized, none outstanding		
Common stock, \$.01 par value, 199 million shares authorized, and 80.6 and 80.1 million issued at 2009 and 2008, respectively	806	801
Capital in excess of par value	272,471	254,216
Retained Earnings	1,150,017	1,065,998
Accumulated other comprehensive income	186,099	139,300
Less: Treasury stock at cost, 13.3 million and 12.5 million shares in 2009 and 2008, respectively	(356,548)	(329,285)
 Total AptarGroup, Inc. Stockholders Equity	 <b>1,252,845</b>	 1,131,030
Noncontrolling interests in subsidiaries	791	768
 Total Stockholders Equity	 <b>1,253,636</b>	 1,131,798
 Total Liabilities and Stockholders Equity	 <b>\$ 1,956,193</b>	 \$ 1,831,822

See accompanying notes to consolidated financial statements.



**Table of Contents**

**AptarGroup, Inc.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

<b>In thousands</b>			
<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>
Cash Flows from Operating Activities:			
Net income	\$ 124,597	\$ 153,501	\$ 141,706
Adjustments to reconcile net income to net cash provided by operations:			
Depreciation	127,709	124,884	118,946
Amortization	5,304	6,261	4,520
Stock option based compensation	9,761	11,054	14,036
Gain on disposition of business, net			(2,232)
Provision for bad debts	701	3,063	1,970
Facilities consolidation and severance expenses	4,435		(43)
Deferred income taxes	(1,329)	(1,326)	(11,783)
Retirement and deferred compensation plans	8,698	14,202	10,084
Equity in results of affiliates in excess of cash distributions received	(164)	(113)	(301)
Changes in balance sheet items, excluding effects from foreign currency adjustments:			
Accounts and notes receivable	34,289	(5,288)	(8,347)
Inventories	21,768	16,800	(26,261)
Prepaid and other current assets	7,437	(10,126)	(2,960)
Accounts payable and accrued liabilities	(22,922)	(13,150)	32,745
Income taxes payable	(2,947)	(23,327)	8,357
Retirement and deferred compensation plan contributions	(32,483)	(12,638)	(8,275)
Other changes, net	8,737	6,414	1,301
Net cash provided by operations	293,591	270,211	273,463
Cash Flows from Investing Activities:			
Capital expenditures	(144,926)	(203,600)	(137,944)
Disposition of property and equipment	1,670	585	6,232
Intangible assets	(308)	(1,323)	(1,195)
Acquisition of business, net of cash acquired	(7,577)	(19,501)	(5,151)
Disposition of business			6,653
Investment in affiliates		(801)	
Notes receivable, net	77	(901)	162
Net cash used by investing activities	(151,064)	(225,541)	(131,243)
Cash Flows from Financing Activities:			
Proceeds from notes payable	63,670		88,699
Repayments of notes payable		(149,123)	
Proceeds from long-term obligations	9,626	100,650	1,298

Edgar Filing: APTARGROUP INC - Form 10-K

Repayments of long-term obligations	<b>(26,993)</b>	(25,227)	(26,030)
Dividends paid	<b>(40,604)</b>	(38,063)	(34,439)
Proceeds from stock option exercises	<b>8,879</b>	13,913	19,050
Purchase of treasury stock	<b>(29,623)</b>	(57,569)	(76,391)
Excess tax benefit from exercise of stock options	<b>1,859</b>	3,797	4,910
Net cash used by financing activities	<b>(13,186)</b>	(151,622)	(22,903)
Effect of Exchange Rate Changes on Cash	<b>11,551</b>	(14,715)	23,846
Net increase/(decrease) in Cash and Equivalents	<b>140,892</b>	(121,667)	143,163
Cash and Equivalents at Beginning of Period	<b>192,072</b>	313,739	170,576
Cash and Equivalents at End of Period	<b>\$ 332,964</b>	\$ 192,072	\$ 313,739
Supplemental Cash Flow Disclosure:			
Interest paid	<b>\$ 17,538</b>	\$ 16,057	\$ 19,981
Income taxes paid	<b>60,931</b>	76,002	63,336
Capital lease obligations			

See accompanying notes to consolidated financial statements.

30 /ATR

2009 Form 10-K

**Table of Contents**

**AptarGroup, Inc.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**  
Years Ended December 31, 2009, 2008 and 2007

thousands

		<b>AptarGroup, Inc. Stockholders Equity</b>							
		<b>Accumulated</b>							
		<b>Retained</b>	<b>Other Comprehensive</b>	<b>Common Stock</b>	<b>Treasury</b>	<b>Capital in</b>	<b>Non-</b>		
		<b>Earnings</b>	<b>Income/(Loss)</b>	<b>Par</b>	<b>Stock</b>	<b>Excess of</b>	<b>Controlling</b>	<b>Total</b>	
		<b>Income</b>	<b>Income/(Loss)</b>	<b>Value</b>	<b>Stock</b>	<b>Par Value</b>	<b>Interest</b>	<b>Equity</b>	
Balance	December 31,								
2006:		\$ 844,921	\$ 109,505	\$ 392	\$ (203,761)	\$ 195,343	\$ 564	\$ 946,900	
Net income		\$ 141,706	141,739				(33)	141,706	
Foreign currency translation adjustments		103,779	103,757				22	103,757	
Changes in unrecognized pension assets/losses and related amortization, net of tax		1,014	1,014					1,014	
Gain on Derivatives, net of tax		18	18					18	
Comprehensive income		\$ 246,517							
Cumulative effect of accounting change		(1,655)						(1,655)	
Stock option exercises & restricted stock vestings				9	4,494	34,072		38,575	
Adjustment for stock repurchases				393		(393)			
Dividends declared on common stock		(34,439)						(34,439)	
Treasury stock purchased					(76,391)			(76,391)	
Balance	December 31,								
2007:		\$ 950,566	\$ 214,294	\$ 794	\$ (275,658)	\$ 229,022	\$ 553	\$ 1,119,529	
Net income		\$ 153,501	153,495				6	153,501	
Foreign currency translation adjustments		(61,229)	(61,250)				21	(61,229)	
Changes in unrecognized pension assets/losses and related amortization, net of tax		(13,164)	(13,164)					(13,164)	

Edgar Filing: APTARGROUP INC - Form 10-K

Treasury Locks, net of									
	(595)		(595)						(595)
Gain on Derivatives, of tax	15		15						
Comprehensive income	\$ 78,528								
Stock option exercises & restricted stock vestings				7	3,942	25,194			29,143
With dividends declared on common stock	(38,063)								(38,063)
On controlling interest entity acquired							188		188
Treasury stock purchased					(57,569)				(57,569)
<b>Balance December 31, 2008:</b>		\$ 1,065,998	\$ 139,300	\$ 801	\$ (329,285)	\$ 254,216	\$ 768	\$ 1,131,700	\$ 1,131,700
Comprehensive income	\$ 124,597	124,623					(26)	124,597	124,597
Foreign currency translation adjustments	44,978		44,929				49	44,978	44,978
Changes in recognized pension assets/losses and related amortization, net of tax	1,790		1,790					1,790	1,790
Changes in treasury stock, net of tax	80		80					80	80
Gain on Derivatives, of tax									
Comprehensive income	\$ 171,445								
Stock option exercises & restricted stock vestings				5	2,708	18,255			20,968
With dividends declared on common stock		(40,604)							(40,604)
Treasury stock purchased					(29,971)				(29,971)
<b>Balance December 31, 2009:</b>		\$ 1,150,017	\$ 186,099	\$ 806	\$ (356,548)	\$ 272,471	\$ 791	\$ 1,253,636	\$ 1,253,636

See accompanying notes to consolidated financial statement.

31 /ATR

2009 Form 10-K

Table of Contents

62



**Table of Contents**

**AptarGroup, Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(Amounts in thousands unless otherwise indicated)

**NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**NATURE OF BUSINESS**

AptarGroup, Inc. is a global company that designs, manufactures and sells consumer product dispensing systems. The Company focuses on providing value-added components to a variety of global consumer product marketers in the personal care, fragrance/cosmetic, pharmaceutical, household and food/beverage industries. The Company has manufacturing facilities located throughout the world including North America, Europe, Asia and South America.

**BASIS OF PRESENTATION**

The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and its subsidiaries. The terms AptarGroup or Company as used herein refer to AptarGroup, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In 2009, the Company revised its presentation relating to French research and development tax credits by reclassifying amounts from Provision for Income Taxes to Selling, Research & Development and Administrative.

**ACCOUNTING ESTIMATES**

The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ( GAAP ). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

**CASH MANAGEMENT**

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

**INVENTORIES**

Inventories are stated at cost, which is lower than market. Costs included in inventories are raw materials, direct labor and manufacturing overhead. The costs of certain domestic and foreign inventories are determined by using the last-in, first-out ( LIFO ) method, while the remaining inventories are valued using the first-in, first-out ( FIFO ) method.

**INVESTMENTS IN AFFILIATED COMPANIES**

The Company accounts for its investments in 20% to 50% owned affiliated companies using the equity method. The Company received dividends from affiliated companies of \$197 and \$182 in 2008 and 2007, respectively. There were no dividends from affiliated companies in 2009.

**PROPERTY AND DEPRECIATION**

Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 25 to 40 years for buildings and improvements, 3 to 10 years for machinery and equipment, and 3 to 7 years for software.

**FINITE-LIVED INTANGIBLE ASSETS**



Finite-lived intangibles, consisting of patents, non-compete agreements and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 3 to 20 years.

#### **GOODWILL AND INDEFINITE-LIVED INTANGIBLE ASSETS**

Management believes the excess purchase price over the fair value of the net assets acquired ( Goodwill ) in purchase transactions has continuing value. Goodwill and indefinite-lived intangible assets must be tested annually, or more frequently as circumstances dictate, for impairment. Management has performed an analysis of the fair values of its reporting units at December 31, 2009. The fair values of the reporting units exceeded the carrying values in 2009, 2008 and 2007 and, therefore, no impairment of goodwill was recorded in the three years.

#### **IMPAIRMENT OF LONG-LIVED ASSETS**

Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset (if any) are less than the carrying value of the asset. When impairment is identified, the carrying amount of the asset is reduced to its fair value. There were no such triggering events identified during 2009.

#### **DERIVATIVES INSTRUMENTS AND HEDGING ACTIVITIES**

Derivative financial instruments are recorded in the consolidated balance sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or accumulated other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction.

32 /ATR

2009 Form 10-K

---

**Table of Contents**

**RESEARCH & DEVELOPMENT EXPENSES**

Research and development costs are expensed as incurred. These costs amounted to \$50.2, \$55.1 and \$53.8 million in 2009, 2008 and 2007, respectively. Prior year amounts have been revised to conform to the current year presentation for French research and development tax credits. The amounts of these credits are \$5.7 and \$2.1 million for 2008 and 2007, respectively.

**INCOME TAXES**

The Company computes taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pretax income for financial accounting purposes. To the extent that these differences create differences between the tax basis of an asset or liability and its reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

Except as noted below, the Company has the expressed intention to reinvest the undistributed earnings of its non-U.S. subsidiaries. A provision has not been made for U.S. or additional foreign taxes on \$748 million of undistributed earnings of non-U.S. subsidiaries, which has been designated as permanently reinvested as of December 31, 2009. These earnings will continue to be reinvested indefinitely and could become subject to additional tax if they were remitted as dividends or lent to a U.S. affiliate, or if the Company should sell its stock in the subsidiaries. It is not practicable to estimate the amount of additional tax that might be payable on these undistributed non-U.S. earnings. The Company will continue to evaluate annually if it will repatriate non-U.S. subsidiary current year earnings or a portion thereof. The Company decided to repatriate a portion of non-U.S. subsidiary current year earnings in 2009, 2008 and 2007 in the amounts of \$78 million, \$63 million and \$18 million, respectively. Tax expense related to the repatriations was provided for in the year the decision was made.

The Company provides a liability for the amount of tax benefits realized from uncertain tax positions. This liability is provided whenever the Company determines that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 for more information.

**TRANSLATION OF FOREIGN CURRENCIES**

The functional currencies of all the Company's foreign operations are the local currencies. Assets and liabilities are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders' Equity. Realized and unrealized foreign currency transaction gains and losses are reflected in income, as a component of miscellaneous income and expense, and represented a gain of \$879 in 2009 and a loss of \$3,293 and \$1,636 in 2008 and 2007, respectively.

**STOCK BASED COMPENSATION**

Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee's retention of the award is no longer contingent on providing subsequent service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately, if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. See Note 15 for more information.

**REVENUE RECOGNITION**

**Product Sales.** In accordance with current accounting standards, the Company's policy is to recognize revenue from product sales when the title and risk of loss has transferred to the customer, when the Company has no remaining obligations regarding the transaction and when collection is reasonably assured. The majority of the Company's products shipped from the U.S. transfers title and risk of loss when the goods leave the Company's shipping location.

The majority of the Company's products shipped from non-U.S. operations transfer title and risk of loss when the goods reach their destination. Tooling revenue is also recognized when the title and risk of loss transfers to the customer.

**Services and Other.** The Company occasionally invoices customers for certain services. The Company also receives revenue from other sources such as license or royalty agreements. Revenue is recognized when services are rendered or rights to use assets can be reliably measured and when collection is reasonably assured. Service and other revenue is not material to the Company's results of operations for any of the years presented.

#### **SUBSEQUENT EVENTS**

The Company has performed an evaluation of subsequent events. No events have occurred that would require adjustment to or disclosure in the condensed consolidated financial statements.

#### **NOTE 2 DISCONTINUED OPERATIONS**

In the fourth quarter of 2007, the Company sold its Australian operation for approximately \$6.7 million in cash. The Australian operation was primarily a sales and distribution facility with light final assembly of some products as well as some molding of dispensing closures. In the future, the Company will continue to sell its products into Australia using the buyer of this company as an agent and distributor. The Company recorded a gain after taxes on this sale of approximately \$2.2 million or approximately \$.03 per diluted share. This net gain has been reported in the consolidated statements of income as discontinued operations.

33 /ATR

2009 Form 10-K

---

**Table of Contents**

The Company elected only to report the net gain as discontinued operations rather than including the full operating results as discontinued operations for all periods presented due to the immateriality of the amounts (less than 1% of net sales and income before income taxes). The Australian entity was previously reported in the Beauty & Home segment.

**NOTE 3 INVENTORIES**

At December 31, 2009 and 2008, approximately 21% and 23%, respectively, of the total inventories are accounted for by the LIFO method. Inventories, by component, consisted of:

	<b>2009</b>	<b>2008</b>
Raw materials	\$ <b>81,452</b>	\$ 93,081
Work-in-process	<b>66,431</b>	55,228
Finished goods	<b>86,192</b>	99,310
Total	<b>234,075</b>	247,619
Less LIFO reserve	<b>(3,268)</b>	(2,844)
Total	\$ <b>230,807</b>	\$ 244,775

**NOTE 4 GOODWILL AND OTHER INTANGIBLE ASSETS**

The Company completed its annual analysis of the fair value of its reporting units as of December 31, 2009 using both a discounted cash flow analysis and market multiple approach, resulting in no impairment.

The changes in the carrying amount of goodwill for the year ended December 31, 2009, are as follows by reporting segment:

	<b>Pharma</b>	<b>Beauty &amp; Home</b>	<b>Closures</b>	<b>Corporate and Other</b>	<b>Total</b>
Goodwill	\$ 28,133	\$ 158,823	\$ 40,085	\$ 1,615	\$ 228,656
Accumulated impairment losses				(1,615)	(1,615)
Balance as of December 31, 2008	\$ 28,133	\$ 158,823	\$ 40,085	\$	\$ 227,041
Acquisitions (See Note 18)		666			666
Foreign currency exchange effects	291	2,327	253		2,871
Goodwill	\$ 28,424	\$ 161,816	\$ 40,338	\$ 1,615	\$ 232,193
Accumulated impairment losses				(1,615)	(1,615)

Balance as of December 31, 2009                    \$   **28,424**    \$   **161,816**    \$   **40,338**    \$                    \$   **230,578**

The table below shows a summary of intangible assets for the years ended December 31, 2009 and 2008.

	Weighted Average Amortization Period (Years)	2009			2008		
		Gross Carrying Amount	Accumulated Amortization	Net Value	Gross Carrying Amount	Accumulated Amortization	Net Value
Amortization intangible assets:							
Patents	14	\$ 19,368	\$ (15,655)	\$ 3,713	\$ 18,854	\$ (13,357)	\$ 5,497
License agreements and other	6	26,261	(20,886)	5,375	25,641	(17,077)	8,564
Total intangible assets	9	\$ 45,629	\$ (36,541)	\$ 9,088	\$ 44,495	\$ (30,434)	\$ 14,061

Aggregate amortization expense for the intangible assets above for the years ended December 31, 2009, 2008 and 2007 was \$5,304, \$6,261, and \$4,520, respectively.

Estimated amortization expense for the years ending December 31 is as follows:

2010	\$ 2,650
2011	\$ 2,301
2012	\$ 1,189
2013	\$ 927
2014	\$ 753

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of December 31, 2009.

34 /ATR

2009 Form 10-K

**Table of Contents****NOTE 5 ACCOUNTS PAYABLE AND ACCRUED LIABILITIES**

At December 31, 2009 and 2008, accounts payable and accrued liabilities consisted of the following:

	<b>2009</b>	<b>2008</b>
Accounts payable, principally trade	\$ <b>109,135</b>	\$ 133,575
Accrued employee compensation costs	<b>78,080</b>	78,502
Unearned income	<b>26,037</b>	30,251
Other accrued liabilities	<b>75,708</b>	68,080
Total	\$ <b>288,960</b>	\$ 310,408

**NOTE 6 INCOME TAXES**

Income from continuing operations before income taxes consists of:

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>
United States	\$ <b>32,938</b>	\$ 21,771	\$ 16,505
International	<b>151,120</b>	204,955	185,576
Total	\$ <b>184,058</b>	\$ 226,726	\$ 202,081

The provision for income taxes from continuing operations is comprised of:

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>
Current:			
U.S. Federal	\$ <b>20,054</b>	\$ 11,520	\$ 12,737
State/Local	<b>1,182</b>	569	459
International	<b>39,554</b>	62,462	61,194
	\$ <b>60,790</b>	\$ 74,551	\$ 74,390

Deferred:

Edgar Filing: APTARGROUP INC - Form 10-K

U.S. Federal/State	\$ 841	\$ (8)	\$ (5,110)
International	(2,170)	(1,318)	(6,673)
	\$ (1,329)	\$ (1,326)	\$ (11,783)
Total	\$ 59,461	\$ 73,225	\$ 62,607

The gain on the sale of the discontinued operations resulted in additional tax expense of \$1,714 in 2007.

To be comparable to the current period, the Company revised its classification relating to a Research & Development credit in France from the Provision for Income Taxes to Selling, Research & Development and Administrative expenses. The amounts of the credit for the years ending December 31, 2009, 2008 and 2007 are \$6.7 million, \$5.7 million and \$2.1 million, respectively.

The difference between the actual income tax provision and the tax provision computed by applying the statutory federal income tax rate of 35.0% in 2009, 2008 and 2007 to income before income taxes is as follows:

Years Ended December 31,	2009	2008	2007
Income tax at statutory rate	\$ 64,420	\$ 79,354	\$ 70,728
State income taxes, net of federal benefit	743	499	189
Research & development credits (non-French)	(826)	(795)	(1,012)
Provision for distribution of current foreign earnings	9,881	3,953	3,524
German tax rate reduction			(2,250)
Italian stimulus	(501)		
Italian government special election	(1,628)		(1,025)
Rate differential on earnings of foreign operations	(13,396)	(10,590)	(6,838)
Other items, net	768	804	(709)
Actual income tax provision	\$ 59,461	\$ 73,225	\$ 62,607
Effective income tax rate	32.3%	32.3%	31.0%

The tax provision for 2009 reflects a \$1.6 million benefit from a special election in Italy related to the revaluation of real property for tax purposes. The tax benefit is attributable to the revaluation of deferred tax liabilities to reflect the higher tax basis.

**Table of Contents**

An additional benefit of \$0.5 million is attributable to depreciation incentives enacted as part of an Italian government stimulus package in 2009.

The tax provision for 2008 reflects the benefit from lower tax rates in Germany and Italy that became effective in 2008. These benefits helped to offset the additional cost from increased repatriation to the US during 2008.

The tax provision for 2007 included a benefit of \$2.3 million from a reduction in the corporate tax rates in Germany. The tax benefits reflected are attributable to the revaluation of the deferred tax assets and liabilities using the new rates as of December 31, 2007. The \$1.0 million reduction from Italy was due to a special election in connection with the enactment of lower corporate tax rates, effective in 2008. The affect of the special election increased current taxes by \$0.6 million, which was offset by a reduction of previously recorded deferred tax liabilities by \$1.6 million.

Significant deferred tax assets and liabilities as of December 31, 2009 and 2008 are comprised of the following temporary differences:

	<b>2009</b>	<b>2008</b>
Deferred Tax Assets:		
Pension liabilities	\$ <b>11,836</b>	\$ 12,976
Stock options	<b>7,625</b>	7,094
Net operating loss carryforwards	<b>6,954</b>	3,021
Inventory	<b>3,997</b>	5,861
Vacation	<b>3,804</b>	3,633
Workers compensation	<b>2,539</b>	3,036
Accruals	<b>2,456</b>	1,371
Allowance for doubtful accounts	<b>2,006</b>	2,307
Foreign tax credit carryforwards		1,127
Other	<b>1,340</b>	578
Total gross deferred tax assets	<b>42,557</b>	41,004
Less valuation allowance	<b>(5,480)</b>	(2,903)
Net deferred tax assets	<b>37,077</b>	38,101
Deferred Tax Liabilities:		
Depreciation and amortization	<b>36,007</b>	36,132
Leases	<b>8,067</b>	8,422
Total gross deferred tax liabilities	<b>44,074</b>	44,554
Net deferred tax liabilities	\$ <b>6,997</b>	\$ 6,453

Gross deferred tax assets for tax loss carryforwards increased to \$6.9 million at December 31, 2009 from \$3.0 million at December 31, 2008. The loss carryforwards exist primarily in non-U.S. jurisdictions, along with U.S. state jurisdictions. Assets of \$3.1 million related to losses in non-U.S. jurisdictions were added as a result of an acquisition completed in 2009. A portion of the non-U.S. losses expire in the years 2012 – 2017. The U.S. state losses expire in the years 2014 – 2023. Management does not believe the benefit of a majority of the non-U.S. losses (\$4.0 million) or the benefit of the U.S. state losses (\$1.4 million) will be realized.



The Company has established a valuation allowance for the deferred tax assets related primarily to the non-U.S. tax loss carryforwards and the U.S. state tax losses not expected to be realized. The valuation allowance increased to \$5.5 million at December 31, 2009 from \$2.9 million at December 31, 2008, reflecting the acquired non-U.S. losses. U.S. foreign tax credit carryforwards decreased to \$0 at December 31, 2009 from \$1.1 million at December 31, 2008. The Company was able to utilize the carryforwards due to increased repatriation to the U.S. in 2009.

No provision for taxes has been made for the cumulative earnings of non-U.S. subsidiaries that are permanently reinvested. These earnings relate to ongoing operations and, at December 31, 2009, were approximately \$748 million. Deferred taxes are provided for current year earnings of non-U.S. subsidiaries when it is decided to remit those earnings to the U.S.

The Company has not provided for taxes on certain tax-deferred income of a foreign operation. The income arose predominately from government grants. Taxes of approximately \$2.6 million would become payable in the event the income was distributed.

36 /ATR

2009 Form 10-K

---

**Table of Contents****INCOME TAX UNCERTAINTIES**

The Company provides a liability for the amount of tax benefits realized from uncertain tax positions. A reconciliation of the beginning and ending amount of income tax uncertainties is as follows:

	<b>2009</b>	<b>2008</b>	<b>2007</b>
Balance at January 1	\$ <b>9,661</b>	\$ 6,492	\$ 7,000
Increases based on tax positions for the current year	\$ <b>1,728</b>	\$ 1,352	1,115
Increases based on tax positions for prior years	<b>1,281</b>	4,362	533
Decreases based on tax positions for prior years	<b>(672)</b>	(1,085)	(182)
Settlements	<b>(168)</b>	(24)	(682)
Lapse of statute of limitations	\$ <b>(1,024)</b>	\$ (1,436)	(1,292)
Balance at December 31	\$ <b>10,806</b>	\$ 9,661	\$ 6,492

The amount of income tax uncertainties that, if recognized, would impact the effective tax rate is \$10.1 million. For the next twelve months, the Company does not anticipate any material changes in its liability for income tax uncertainties.

The Company recognizes interest and penalties accrued related to unrecognized tax benefits as a component of income taxes. During 2009, the Company recognized \$0.4 million in interest and penalties. The Company had approximately \$1.8 million and \$1.4 million accrued for the payment of interest and penalties as of December 31, 2009 and 2008, respectively.

The Company or its subsidiaries file income tax returns in the U.S. Federal jurisdiction and various state and foreign jurisdictions. The major tax jurisdictions the Company files in, with the years still subject to income tax examinations, are listed below:

<b>Major Tax Jurisdiction</b>	<b>Tax Years Subject to Examination</b>
United States Federal	2006 2009
United States State	2005 2009
France	2006 2009
Germany	2006 2009
Italy	2004 2009
Switzerland	1998 2009

**NOTE 7 DEBT**

Average borrowings under unsecured lines of credit were \$65.3 million and \$156.3 million for 2009 and 2008, respectively, and the average annual interest rate on short-term notes payable, which is included in the notes payable caption under current liabilities of the balance sheet was approximately 1.6% for 2009 and 3.6% for 2008. There are no compensating balance requirements associated with short-term borrowings. The Company has a \$200 million revolving credit facility. Under this credit agreement, interest on borrowings is payable at a rate equal to London Interbank Offered Rates ( LIBOR ) plus an amount based on the financial condition of the Company. The Company is

required to pay a fee for this commitment. Commitment or facility fee payments in 2009, 2008 and 2007 were not significant. The amounts borrowed under this agreement were \$100 million and \$25 million at December 31, 2009 and 2008, respectively.

The revolving credit and the senior unsecured debt agreements contain covenants, with which the Company is in compliance, that include certain financial tests.

At December 31, the Company's long-term obligations consisted of the following:

	<b>2009</b>	<b>2008</b>
Notes payable 0.5% - 16.5%, due in monthly and annual installments through 2015	\$ <b>10,750</b>	\$ 4,787
Senior unsecured notes 6.6%, due in installments through 2011	<b>43,374</b>	65,268
Senior unsecured notes 5.1%, due in 2011	<b>25,000</b>	25,000
Senior unsecured notes 5.4% due in 2013	<b>25,000</b>	25,000
Senior unsecured notes 6.0% due in 2016	<b>50,000</b>	50,000
Senior unsecured notes 6.0% due in 2018	<b>75,000</b>	75,000
Capital lease obligations	<b>5,607</b>	6,533
	<b>234,731</b>	251,588
Current maturities of long-term obligations	<b>(25,115)</b>	(24,700)
Total long-term obligations	<b>\$ 209,616</b>	\$ 226,888

Based on the borrowing rates currently available to the Company for long-term obligations with similar terms and average maturities, the fair value of the Company's long-term obligations approximates its book value.

37 /ATR

2009 Form 10-K

**Table of Contents**

Aggregate long-term maturities, excluding capital lease obligations, which is discussed in Note 8, due annually for the five years and thereafter beginning in 2010 are \$24,476, \$48,621, \$2,146, \$26,995, \$1,867 and \$125,019 thereafter.

**NOTE 8 LEASE COMMITMENTS**

The Company leases certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and capital leases expiring at various dates through the year 2029. Most of the operating leases contain renewal options and certain leases include options to purchase during or at the end of the lease term.

Amortization expense related to capital leases is included in depreciation expense. Rent expense under operating leases (including taxes, insurance and maintenance when included in the rent) amounted to \$24,129, \$24,382 and \$22,595 in 2009, 2008 and 2007, respectively.

Assets recorded under capital leases consist of:

	<b>2009</b>	<b>2008</b>
Buildings	\$ <b>23,117</b>	\$ 22,393
Machinery and equipment	<b>9,246</b>	12,750
	<b>32,363</b>	35,143
Accumulated depreciation	<b>(19,298)</b>	(19,613)
	<b>\$ 13,065</b>	\$ 15,530

Future minimum payments, by year and in the aggregate, under the capital leases and noncancelable operating leases with initial or remaining terms of one year or more consisted of the following at December 31, 2009:

	<b>Capital Leases</b>	<b>Operating Leases</b>
2010	\$ 765	\$ 14,273
2011	1,309	10,187
2012	1,016	6,850
2013	587	2,821
2014	587	1,675
Subsequent to 2014	3,475	8,724
Total minimum lease payments	7,739	\$ 44,530
Amounts representing interest	(2,132)	
Present value of future minimum lease payments	5,607	

Lease amount due in one year	(639)
Total	\$ 4,968

38 /ATR

2009 Form 10-K

---

**Table of Contents****NOTE 9 RETIREMENT AND DEFERRED COMPENSATION PLANS**

The Company has various noncontributory retirement plans covering certain of its domestic and foreign employees. Benefits under the Company's retirement plans are based on participants' years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under the Company's domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (ERISA). Certain pension commitments under its foreign plans are also funded according to local requirements or at the Company's discretion.

In 2008, new regulations in France raised the pension benefits of certain French employees under collective bargaining agreements. The impact of these regulations increased the benefit obligation of our foreign plans and is reflected as a plan amendment.

The following table presents the changes in the benefit obligations and plan assets for the most recent two years for the Company's domestic and foreign plans.

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
<b>Change in benefit obligation:</b>				
Benefit obligation at beginning of year	\$ <b>64,954</b>	\$ 55,017	\$ <b>43,816</b>	\$ 40,735
Service cost	<b>4,363</b>	4,098	<b>1,766</b>	1,644
Interest cost	<b>3,820</b>	3,514	<b>2,503</b>	2,174
Prior service cost				112
Plan amendments				5,183
Curtailment/Settlement	<b>(560)</b>		<b>(151)</b>	
Actuarial loss/(gain)	<b>2,150</b>	3,586	<b>(316)</b>	(3,128)
Benefits paid	<b>(3,061)</b>	(1,261)	<b>(3,264)</b>	(1,224)
Foreign currency translation adjustment			<b>976</b>	(1,680)
Benefit obligation at end of year	\$ <b>71,666</b>	\$ 64,954	\$ <b>45,330</b>	\$ 43,816

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
<b>Change in plan assets:</b>				
Fair value of plan assets at beginning of year	\$ <b>36,953</b>	\$ 46,116	\$ <b>16,560</b>	\$ 14,495
Actual return on plan assets	<b>6,474</b>	(11,152)	<b>1,120</b>	(1,331)
Employer contribution	<b>9,441</b>	3,250	<b>19,042</b>	5,388
Settlements	<b>(560)</b>			
Benefits paid	<b>(3,061)</b>	(1,261)	<b>(3,341)</b>	(1,224)
Foreign currency translation adjustment			<b>412</b>	(768)
Fair value of plan assets at end of year	\$ <b>49,247</b>	\$ 36,953	\$ <b>33,793</b>	\$ 16,560

**Funded status at end of year** \$ (22,419) \$ (28,001) \$ (11,538) \$ (27,256)

The following table presents the funded status amounts recognized in the Company's Consolidated Balance Sheet as of December 31, 2009 and 2008.

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Non-current assets	\$	\$	\$ 779	\$ 690
Current liabilities	(514)	(291)	(570)	(557)
Non-current liabilities	(21,905)	(27,710)	(11,747)	(27,389)
	\$ (22,419)	\$ (28,001)	\$ (11,538)	\$ (27,256)

The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive loss as of December 31, 2009 and 2008.

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Net actuarial loss	\$ 17,552	\$ 18,535	\$ 5,160	\$ 6,347
Net prior service cost	16	21	5,292	5,787
Tax effects	(6,588)	(6,958)	(3,348)	(3,831)
	\$ 10,980	\$ 11,598	\$ 7,104	\$ 8,303

**Table of Contents**

Changes in benefit obligations and plan assets recognized in other comprehensive income in 2009 are as follows:

	<b>Domestic Plans</b>	<b>Foreign Plans</b>
Current year actuarial gain	\$ (773)	\$ (392)
Amortization of gain	(211)	(625)
Current year prior service		(38)
Amortization of prior service cost	(4)	(423)
	\$ (988)	\$ (1,478)

The following table presents the amounts in accumulated other comprehensive loss as of December 31, 2009 expected to be recognized as components of periodic benefit cost in 2010.

	<b>Domestic Plans</b>	<b>Foreign Plans</b>
Amortization of net loss	\$ 542	\$ 273
Amortization of prior service cost	4	382
	\$ 546	\$ 655

**Components of net periodic benefit cost:**

	<b>Domestic Plans</b>		
	<b>2009</b>	<b>2008</b>	<b>2007</b>
Service cost	\$ 4,363	\$ 4,098	\$ 3,879
Interest cost	3,820	3,514	2,985
Expected return on plan assets	(3,726)	(3,107)	(2,726)
Amortization of net loss	239	81	218
Amortization of prior service cost	4	4	4
Net periodic benefit cost	\$ 4,700	\$ 4,590	\$ 4,360
Settlement	146		
Total Net periodic benefit cost	\$ 4,846	\$ 4,590	\$ 4,360

**Foreign Plans**



	<b>2009</b>	<b>2008</b>	<b>2007</b>
Service cost	\$ <b>1,745</b>	\$ 1,644	\$ 1,584
Interest cost	<b>2,502</b>	2,174	1,681
Expected return on plan assets	<b>(980)</b>	(830)	(727)
Amortization of net loss	<b>625</b>	748	513
Amortization of prior service cost	<b>376</b>	79	74
Net periodic benefit cost	\$ <b>4,268</b>	\$ 3,815	\$ 3,125
Curtailement	<b>(105)</b>		
Total Net periodic benefit cost	\$ <b>4,163</b>	\$ 3,815	\$ 3,125

The accumulated benefit obligation ( ABO ) for the Company's domestic defined benefit pension plans was \$62.6 million and \$56.6 million at December 31, 2009 and 2008, respectively. The accumulated benefit obligation for the Company's foreign defined benefit pension plans was \$37.8 million and \$36.9 million at December 31, 2009 and 2008, respectively.

The following table provides the projected benefit obligation ( PBO ), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2009 and 2008.

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Projected benefit obligation	\$ <b>71,666</b>	\$ 64,954	\$ <b>39,586</b>	\$ 41,959
Accumulated benefit obligation	<b>62,558</b>	56,601	<b>33,431</b>	35,283
Fair value of plan assets	<b>49,247</b>	36,953	<b>28,291</b>	14,848

40 /ATR

2009 Form 10-K

**Table of Contents**

The following table provides the PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2009 and 2008.

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Projected benefit obligation	\$ <b>71,666</b>	\$ 64,954	\$ <b>43,143</b>	\$ 42,885
Accumulated benefit obligation	<b>62,558</b>	56,601	<b>35,903</b>	36,083
Fair value of plan assets	<b>49,247</b>	36,953	<b>30,827</b>	14,940

**Assumptions:**

	<b>Domestic Plans</b>		<b>Foreign Plans</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Weighted-average assumptions used to determine benefit obligations at December 31:				
Discount rate	<b>5.90%</b>	6.00%	<b>5.55%</b>	5.60%
Rate of compensation increase	<b>4.00%</b>	4.00%	<b>3.00%</b>	3.00%
Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31:				
Discount rate	<b>6.00%</b>	6.40%	<b>5.60%</b>	5.25%
Expected long-term return on plan assets	<b>7.00%</b>	7.00%	<b>6.00%</b>	6.00%
Rate of compensation increase	<b>4.00%</b>	4.50%	<b>3.00%</b>	3.00%

The Company develops the expected long-term rate of return assumptions based on historical experience and by evaluating input from the plans' asset managers, including the managers' review of asset class return expectations and benchmarks, economic indicators and long-term inflation assumptions.

In order to determine the 2010 net periodic benefit cost, the Company expects to use the December 31, 2009 discount rates, rates of compensation increase assumptions and the expected long-term returns on domestic and foreign plan assets used in 2009.

The Company's domestic and foreign pension plan weighted-average asset allocations at December 31, 2009 and 2008 by asset category are as follows:

**Plan Assets:****Domestic Plans Assets****Foreign Plans Assets**

	<b>at December 31,</b>		<b>at December 31,</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Equity securities	<b>55%</b>	54%	<b>17%</b>	30%
Fixed income securities	<b>35%</b>	28%	<b>32%</b>	60%
Infrastructure	<b>9%</b>	14%		
Money market	<b>1%</b>	4%	<b>47%</b>	
Real estate			<b>4%</b>	10%
Total	<b>100%</b>	100%	<b>100%</b>	100%

The Company's investment strategy for its domestic and foreign pension plans is to maximize the long-term rate of return on plan assets within an acceptable level of risk. The investment policy strives to have assets sufficiently diversified so that adverse or unexpected results from one security type will not have an unduly detrimental impact on the entire portfolio and accordingly, establishes a target allocation for each asset category within the portfolio. The domestic plan asset allocation is reviewed on a quarterly basis and the foreign plan asset allocation is reviewed annually. Rebalancing occurs as needed to comply with the investment strategy. The domestic plan target allocation for 2010 is 60% equity securities and 40% fixed income securities and infrastructure. The foreign plan target allocation for 2010 is 42% equity securities, 52% fixed income securities, 4% real estate, and 2% money market. The Company contributed approximately \$15.0 million in December 2009 to partially fund its previously unfunded German pension plans. These funds were invested in money market funds at December 31, 2009 and will be reinvested according to the foreign plan target allocation in 2010.

41 /ATR

2009 Form 10-K

**Table of Contents**

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3: Unobservable inputs reflecting management's own assumptions about the inputs used in pricing the asset or liability.

(In thousands \$)	Domestic Fair Value Measurement at December 31, 2009				Foreign Fair Value Measurement at December 31, 2009			
	Total	(Level 1)	(Level 2)	(Level 3)	Total	(Level 1)	(Level 2)	(Level 3)
<b>Cash and Short Term</b>								
<b>Securities (a)</b>	\$ 318	\$ 318	\$	\$	\$ 15,040	\$ 15,040	\$	\$
USD	318	318			6,783	6,783		
EUR					8,257	8,257		
<b>Equity Securities (a)</b>	\$ 27,106	\$ 27,106						
US Large Cap								
Equities		11,508						
US Small Cap								
Equities		8,081						
International Equities		7,517						
<b>Core Fixed Income (a)</b>	\$ 17,256	\$ 17,256						
<b>Investment Funds</b>					\$ 18,752	\$ 2,717	\$ 16,035	
Mutual Funds in								
Equities (a)					2,717	2,717		
Mutual Funds								
Diversified (b)					16,035		16,035	
<b>Infrastructure (c)</b>	\$ 4,567			\$ 4,567				
<b>Total Investments</b>	\$ 49,247	\$ 44,680	\$	\$ 4,567	\$ 33,793	\$ 17,757	\$ 16,035	\$

(a) Based on third party quotation from financial institution

(b) Based on observable market transactions

(c) Based on a quarterly statement prepared by the fund manager that reflects contributions, distributions and realized/unrealized gains and losses.

The following table sets forth a summary of changes in fair value of the pension plan investments classified as Level 3 for the year ended December 31, 2009.

		<b>Infrastructure Fund</b>
Balance, beginning of year	\$	4,364
Return on assets		283
Admin fees and other		(80)
Balance, end of year	\$	4,567

### **CONTRIBUTIONS**

Annual cash contributions to fund pension costs accrued under the Company's domestic plans are generally at least equal to the minimum funding amounts required by ERISA. The Company contributed \$9.4 million to its domestic defined benefit plans in 2009 and expects to contribute approximately \$5.0 million in 2010. Contributions to fund pension costs accrued under the Company's foreign plans are made in accordance with local laws or at the Company's discretion. The Company contributed approximately \$19.0 million to its foreign defined benefit plan in 2009 and expects to contribute approximately \$7.0 million in 2010.

### **ESTIMATED FUTURE BENEFIT PAYMENTS**

As of December 31, 2009, the Company expects the plans to make the following estimated benefit payments relating to its defined benefit plans over the next ten years:

	<b>Domestic Plans</b>	<b>Foreign Plans</b>
2010	\$ 4,194	\$ 3,592
2011	3,998	1,716
2012	4,978	1,801
2013	5,565	1,975
2014	5,801	2,738
2015 - 2019	33,848	17,169

42 /ATR

2009 Form 10-K

**Table of Contents**

**OTHER PLANS**

The Company has a non-qualified supplemental pension plan for domestic employees which provides for pension amounts that would have been payable from the Company's principal domestic pension plan if it were not for limitations imposed by income tax regulations. The liability for this plan, which is not funded, was \$3.5 million and \$3.2 million at December 31, 2009 and 2008, respectively. This amount is included in the liability for domestic plans shown above.

The Company has a defined contribution 401(k) employee savings plan available to substantially all domestic employees. Company matching contributions are made in cash up to a maximum of 3% of the participating employee's salary subject to income tax regulations. For each of the years ended December 31, 2009, 2008 and 2007, total contributions made by the Company for these plans were approximately \$2.2 million, \$2.2 million and \$1.9 million, respectively.

The Company has several foreign defined contribution plans, which require the Company to contribute a percentage of the participating employee's salary according to local regulations. For each of the years ended December 31, 2009, 2008 and 2007, total contributions made by the Company for these plans were approximately \$1.8 million, \$1.8 million and \$2.4 million, respectively.

The Company has no additional postretirement or postemployment benefit plans.

**NOTE 10 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES**

The Company maintains a foreign exchange risk management policy designed to establish a framework to protect the value of the Company's non-functional denominated transactions from adverse changes in exchange rates. Sales of the Company's products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales can impact the Company's results of operations. The Company's policy is not to engage in speculative foreign currency hedging activities, but to minimize its net foreign currency transaction exposure defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. The Company may use foreign currency forward exchange contracts, options and cross currency swaps to hedge these risks.

The Company maintains an interest rate risk management strategy to minimize significant, unanticipated earnings fluctuations that may arise from volatility in interest rates.

For derivative instruments designated as hedges, the Company formally documents the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur.

**FAIR VALUE HEDGES**

The Company has an interest rate swap to convert a portion of its fixed-rate debt into variable-rate debt. Under the interest rate swap contract, the Company exchanges, at specified intervals, the difference between fixed-rate and floating-rate amounts, which are calculated based on an agreed upon notional amount.

As of December 31, 2009, the Company has recorded the fair value of derivative instruments of \$574 thousand in miscellaneous other assets with an offsetting adjustment to debt related to a fixed-to-variable interest rate swap agreement with a notional principal value of \$10 million. No gain or loss was recorded in the income statement in 2009, 2008 or 2007 as any hedge ineffectiveness for the periods was immaterial.

**CASH FLOW HEDGES**

As of December 31, 2009, the Company had one foreign currency cash flow hedge. A French entity of AptarGroup, AptarGroup Holding SAS, has hedged the risk of variability in Euro equivalent associated with the cash flows of an intercompany loan granted in Brazilian Real. The forward contracts utilized were designated as a hedge of the changes in the cash flows relating to the changes in foreign currency rates relating to the loan and related forecasted interest. The notional amount of the foreign currency forward contracts utilized to hedge cash flow exposure was 4.2 million Brazilian Real (\$2.4 million) as of December 31, 2009. The notional amount of the foreign currency forward contracts utilized to hedge cash flow exposure was 5.5 million Brazilian Real (\$2.4 million) as of December 31, 2008.

During the year ended December 31, 2009, the Company did not recognize any net gain (loss) as any hedge ineffectiveness for the period was immaterial, and the Company did not recognize any net gain (loss) related to the portion of the hedging instrument excluded from the assessment of hedge effectiveness. The Company's foreign currency forward contracts hedge forecasted transactions for approximately two years (March 2012).

#### **HEDGE OF NET INVESTMENTS IN FOREIGN OPERATIONS**

A significant number of the Company's operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of the Company's foreign entities. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on the Company's financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. The Company in some cases maintains debt in these subsidiaries to offset the net asset exposure. The Company does not

43 /ATR

2009 Form 10-K

---

**Table of Contents**

otherwise actively manage this risk using derivative financial instruments. In the event the Company plans on a full or partial liquidation of any of its foreign subsidiaries where the Company's net investment is likely to be monetized, the Company will consider hedging the currency exposure associated with such a transaction.

**OTHER**

As of December 31, 2009, the Company has recorded the fair value of foreign currency forward exchange contracts of \$1.2 million in accounts payable and accrued liabilities, \$902 thousand in prepayments and other and \$2.5 million in deferred and other non-current liabilities in the balance sheet. All forward exchange contracts outstanding as of December 31, 2009 had an aggregate contract amount of \$89.9 million.

**Fair Value of Derivative Instruments in the Statement of Financial Position as of December 31, 2009**  
(In thousands)

Derivative Contracts Designated as Hedging Instruments	Balance Sheet Location	Derivative Assets	Balance Sheet Location	Derivative Liabilities
		December 31, 2009		December 31, 2009
Interest Rate Contracts	Other Assets Miscellaneous	\$ 574		\$
Foreign Exchange Contracts			Accounts Payable and Accrued Liabilities	293
Foreign Exchange Contracts			Deferred and other non- current liabilities	437
		574		730
<b>Derivative Contracts Not Designated as Hedging Instruments</b>				
Foreign Exchange Contracts	Prepayments & Other	902	Accounts Payable and Accrued Liabilities	885
Foreign Exchange Contracts			Deferred and other non- current liabilities	2,020
		\$ 902		\$ 2,905
Total Derivative Contracts		\$ 1,476		\$ 3,635

**The Effect of Derivative Instruments on the Statements of Financial Performance  
for the Three and Twelve Months Ended December 31, 2009**



<b>Derivatives in Fair Value Hedging Relationships</b>	<b>Location of Gain or (Loss) Recognized in Income on Derivative</b>	<b>Amount of Gain or (Loss) Recognized in Income on Derivative</b>	
		<b>Three Months Ended December 31, 2009</b>	<b>Twelve Months Ended December 31, 2009</b>
Interest Rate Contracts	(a)	\$	\$

(a) Interest rate swap uses the short-cut method which adjusts short term debt. Therefore, there is no net impact on income.

44 /ATR

2009 Form 10-K

---

**Table of Contents****Three Months Ended December 31, 2009**

					Amount of Gain or (Loss) Recognized in Income of Derivative (Ineffective Portion and Amount Excluded From Effectiveness Testing) 2009
	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) 2009	Location of Gain or (Loss) Reclassified From Accumulated OCI Into Income (Effective Portion) 2009	Amount of Gain or (Loss) From Accumulated OCI Into Income (Effective Portion) 2009	Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) 2009	Amount of Gain or (Loss) Recognized in Income of Derivative (Ineffective Portion and Amount Excluded From Effectiveness Testing) 2009
Derivatives in Cash					
Flow Hedging					
Relationships					
Foreign Exchange Contracts	\$ (2)		\$		\$
Total	\$ (2)		\$		\$

**Year Ended December 31, 2009**

					Amount of Gain or (Loss) Recognized in Income of Derivative (Ineffective Portion and Amount Excluded From Effectiveness Testing) 2009
	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) 2009	Location of Gain or (Loss) Reclassified From Accumulated OCI Into Income (Effective Portion) 2009	Amount of Gain or (Loss) From Accumulated OCI Into Income (Effective Portion) 2009	Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) 2009	Amount of Gain or (Loss) Recognized in Income of Derivative (Ineffective Portion and Amount Excluded From Effectiveness Testing) 2009
Derivatives in Cash					

<b>Flow Hedging Relationships</b>	<b>Portion) 2009</b>	<b>OCI Into Income (Effective Portion)</b>	<b>(Effective Portion) 2009</b>	<b>Effectiveness Testing)</b>	<b>Testing) 2009</b>
Foreign Exchange Contracts	\$		\$		\$
Total	\$		\$		\$

<b>Derivatives Not Designated as Hedging Instruments</b>	<b>Location of Gain or (Loss) Recognized in Income on Derivative</b>	<b>Amount of Gain or (Loss) Recognized in Income on Derivative</b>	
		<b>Three Months Ended December 31, 2009</b>	<b>Twelve Months Ended December 31, 2009</b>
Foreign Exchange Contracts	Other Income (Expense), Miscellaneous, net	\$ 336	\$ (2,917)

#### NOTE 11 COMMITMENTS AND CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. Management believes the resolution of these claims and lawsuits will not have a material adverse or positive effect on the Company's financial position, results of operations or cash flows.

Under its Certificate of Incorporation, the Company has agreed to indemnify its officers and directors for certain events or occurrences while the officer or director is, or was serving, at its request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a directors and officers liability insurance policy that covers a portion of its exposure. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no liabilities recorded for these agreements as of December 31, 2009.

#### NOTE 12 PREFERRED STOCK PURCHASE RIGHTS

The Company has a preferred stock purchase rights plan (the "Rights Plan") and each share of common stock has one-half of a preferred share purchase right (a "Right"). Under the terms of the Rights Plan, if a person or group acquires 15% or more of the

**Table of Contents**

outstanding common stock, each Right will entitle its holder (other than such person or members of such group) to purchase, at the Right's then current exercise price, a number of shares of the Company's common stock having a market value of twice such price. In addition, under certain circumstances if the Company is acquired in a merger or other business combination transaction, each Right will entitle its holder to purchase, at the Right's then current exercise price, a number of the acquiring company's common shares having a market value of twice such price. Each Right entitles the holder under certain circumstances to buy one one-thousandth of a share of Series B junior participating preferred stock, par value \$.01 per share, at an exercise price of \$150. Each share of Series B junior participating preferred stock will entitle its holder to 2,000 votes and will have a minimum preferential quarterly dividend payment equal to the greater of \$1 per share or 2,000 times the amount paid to holders of common stock. Currently, 99,000 shares of Series B junior participating preferred stock have been reserved. The Rights will expire on April 7, 2013, unless previously exercised or redeemed at the option of the Board of Directors for \$.01 per Right.

**NOTE 13 STOCK REPURCHASE PROGRAM**

The Company repurchased approximately 0.9 million and 1.4 million shares of its outstanding common stock in 2009 and 2008, respectively, at a total cost of \$30.0 million and \$57.6 million in 2009 and 2008, respectively. Shares repurchased are returned to Treasury Stock. The Company has a remaining authorization at December 31, 2009 to repurchase 3.7 million additional shares. The timing of and total amount expended for the share repurchase program will depend upon market conditions.

**NOTE 14 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)**

Accumulated other comprehensive income consists of treasury locks, foreign currency translation adjustments, net gain (loss) on derivatives and pension liability adjustments. The following table summarized our accumulated other comprehensive income activity for the years ended December 31, 2009, 2008 and 2007:

	<b>Foreign Currency Translation Adjustments</b>	<b>Net Gain/ (Loss) on Derivatives</b>	<b>Other Adjustments</b>	<b>Accumulated Other Comprehensive Income</b>
	(1)	(2)	(3)	
Balance December 31, 2006	117,284	\$ (28)	(7,751)	109,505
Period change	103,757	18	1,014	104,789
Balance December 31, 2007	221,041	(10)	(6,737)	214,294
Period change	(61,250)	15	(13,759)	(74,994)
Balance December 31, 2008	159,791	5	(20,496)	139,300
Period change	44,929	(1)	1,871	46,799
Balance December 31, 2009	<b>\$ 204,720</b>	<b>\$ 4</b>	<b>\$ (18,625)</b>	<b>\$ 186,099</b>

(1) Income taxes are generally not provided for foreign currency translation adjustments.

- (2) Amount includes an increase in deferred income tax assets by \$0.4 million related to the net loss on derivatives at December 31, 2009, and a reduction of deferred income tax assets by \$5 and \$6 for the net gain on derivatives at December 31, 2008 and 2007, respectively.
- (3) Amounts include the effects of deferred income tax assets provided for pension liability adjustments at December 31, 2009, 2008 and 2007 of \$9,936, \$10,789 and \$2,945, respectively, and change in treasury locks of \$80 and \$595, respectively, at December 31, 2009 and 2008.

NOTE 15 STOCK-BASED COMPENSATION

The Company issues stock options and restricted stock units to employees under Stock Awards Plans approved by shareholders. Stock options are issued to non-employee directors for their services as directors under Director Stock Option Plans approved by shareholders. Options are awarded with the exercise price equal to the market price on the date of grant and generally become exercisable over three years and expire 10 years after grant. Restricted stock units generally vest over three years.

Compensation expense recorded attributable to stock options for the year ended December 31, 2009 was approximately \$9.8 million (\$7.3 million after tax), or \$0.11 per share basic and \$0.10 per share diluted. The income tax benefit related to this compensation expense was approximately \$2.4 million. Approximately \$8.7 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense recorded attributable to stock options for the year ended December 31, 2008 was approximately \$11.1 million (\$8.0 million after tax), or \$0.12 per share basic and \$0.11 per share diluted. The income tax benefit related to this

46 /ATR

2009 Form 10-K

---

**Table of Contents**

compensation expense was approximately \$3.1 million. Approximately \$10.0 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense recorded attributable to stock options for the year ended December 31, 2007 was approximately \$14.0 million (\$10.5 million after tax), or \$0.15 per share basic and diluted. The income tax benefit related to this compensation expense was approximately \$3.5 million. Approximately \$13.1 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales.

The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the Stock Awards Plans was \$7.33, \$10.02 and \$9.32 per share in 2009, 2008 and 2007, respectively. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Stock Awards Plans: Years Ended December 31,	2009	2008	2007
Dividend Yield	1.6%	1.4%	1.4%
Expected Stock Price Volatility	24.2%	22.4%	24.6%
Risk-free Interest Rate	2.2%	3.7%	4.8%
Expected Life of Option (years)	6.9	6.9	7.0

The fair value of stock options granted under the Director Stock Option Plan was \$7.90. The fair value of stock options granted under the Director Stock Option Plan in 2008 was \$12.08. There were no stock options granted under the Director Stock Option Plans in 2007. These values were estimated on the respective date of the grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Stock Director Stock Option Plans: Years Ended December 31,	2009	2008	2007
Dividend Yield	1.7%	1.3%	
Expected Stock Price Volatility	24.9%	22.3%	
Risk-free Interest Rate	3.1%	3.8%	
Expected Life of Option (years)	6.9	6.9	

47 /ATR

2009 Form 10-K

**Table of Contents**

A summary of option activity under the Company's stock option plans as of December 31, 2009, and changes during the period then ended is presented below:

	Stock Awards Plans		Director Stock Option Plans	
	Shares	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
<b>Outstanding, January 1, 2009</b>	<b>7,743,827</b>	<b>\$ 24.51</b>	<b>157,000</b>	<b>\$ 23.25</b>
<b>Granted</b>	<b>1,252,270</b>	<b>30.56</b>	<b>48,000</b>	<b>30.17</b>
<b>Exercised</b>	<b>(598,133)</b>	<b>14.24</b>		
<b>Forfeited or expired</b>	<b>(21,287)</b>	<b>32.05</b>		
<b>Outstanding at December 31, 2009</b>	<b>8,376,677</b>	<b>\$ 26.13</b>	<b>205,000</b>	<b>\$ 24.87</b>
<b>Exercisable at December 31, 2009</b>	<b>5,915,649</b>	<b>\$ 23.34</b>	<b>157,000</b>	<b>\$ 23.25</b>

Weighted-Average Remaining Contractual Term (Years):

<b>Outstanding at December 31, 2009</b>	<b>5.9</b>	<b>4.9</b>
<b>Exercisable at December 31, 2009</b>	<b>4.8</b>	<b>4.1</b>

Aggregate Intrinsic Value:

<b>Outstanding at December 31, 2009</b>	<b>\$ 82,668</b>	<b>\$ 2,262</b>
<b>Exercisable at December 31, 2009</b>	<b>\$ 74,078</b>	<b>\$ 1,995</b>

Intrinsic Value of Options Exercised During the Years Ended:

<b>December 31, 2009</b>	<b>\$ 10,916</b>	<b>\$</b>
December 31, 2008	\$ 21,645	\$
December 31, 2007	\$ 26,028	\$ 1,262

The fair value of shares vested during the years ended December 31, 2009, 2008 and 2007 was \$11.0 million, \$10.4 million and \$9.5 million, respectively. Cash received from option exercises was approximately \$8.9 million and the tax deduction from option exercises was approximately \$2.7 million in the year ended December 31, 2009. As of December 31, 2009, the remaining valuation of stock option awards to be expensed in future periods was \$5.4 million and the related weighted-average period over which it is expected to be recognized is 1.3 years.

The fair value of restricted stock grants is the market price of the underlying shares on the grant date. A summary of restricted stock unit activity as of December 31, 2009, and changes during the period then ended is presented below:

**Weighted-Average**

	Shares		Grant-Date Fair Value
<b>Nonvested at January 1, 2009</b>	<b>21,739</b>	<b>\$</b>	<b>32.03</b>
<b>Granted</b>	<b>3,792</b>		<b>29.72</b>
<b>Vested</b>	<b>(10,353)</b>		<b>31.16</b>
<b>Nonvested at December 31, 2009</b>	<b>15,178</b>	<b>\$</b>	<b>32.04</b>

Compensation expense recorded attributable to restricted stock unit grants for the years ended December 31, 2009, 2008 and 2007 was approximately \$143 thousand, \$378 thousand and \$449 thousand, respectively. The fair value of units vested during the years ended December 31, 2009, 2008 and 2007 was \$323 thousand, \$262 thousand and \$212 thousand, respectively. The intrinsic value of units vested during the years ended December 31, 2009, 2008 and 2007 was \$319 thousand, \$324 thousand and \$290 thousand, respectively. As of December 31, 2009, there was \$3 thousand of total unrecognized compensation cost relating to restricted stock unit awards which is expected to be recognized over a weighted average period of one year.

48 /ATR

2009 Form 10-K



Table of ContentsNOTE 16 EARNINGS PER SHARE

The reconciliation of basic and diluted earnings per share for the years ended December 31, 2009, 2008 and 2007 are as follows:

	<b>2009</b>	<b>2008</b>	<b>2007</b>
Basic earnings per share computation Numerator:			
Income from continuing operations	\$ 124,597	\$ 153,501	\$ 139,474
Income from discontinued operations, net of tax			2,232
Net Income	\$ 124,597	\$ 153,501	\$ 141,706
Denominator:			
Basic shares outstanding	67,643	67,851	68,769
Basic earnings per share from continuing operations	\$ 1.84	\$ 2.26	\$ 2.03
Basic earnings per share from discontinued operations			0.03
Basic net earnings per share	\$ 1.84	\$ 2.26	\$ 2.06
Diluted earnings per share computation Numerator:			
Income from continuing operations	\$ 124,597	\$ 153,501	\$ 139,474
Income from discontinued operations, net of tax			2,232
Net Income	\$ 124,597	\$ 153,501	\$ 141,706
Denominator:			
Basic shares outstanding	67,643	67,851	68,769
Effect of Dilutive Securities			
Stock options	2,136	2,657	2,741
Restricted stock	6	10	13
Diluted shares outstanding	69,785	70,518	71,523
Diluted earnings per share from continuing operations	\$ 1.79	\$ 2.18	\$ 1.95
Diluted earnings per share from discontinued operations			0.03
Diluted net earnings per share	\$ 1.79	\$ 2.18	\$ 1.98

NOTE 17 SEGMENT INFORMATION

The Company operates in the packaging components industry, which includes the development, manufacture and sale of consumer product dispensing systems. Operations that sell spray and lotion dispensing systems primarily to the personal care, fragrance/cosmetic and household markets form the Beauty & Home segment. Operations that sell dispensing systems to the pharmaceutical market form the Pharma segment. Operations that sell closures to each market served by AptarGroup form the Closures segment.

The accounting policies of the segments are the same as those described in Note 1, Summary of Significant Accounting Policies. The Company evaluates performance of its business segments and allocates resources based upon earnings before interest expense in excess of interest income, stock option and corporate expenses and income taxes (collectively referred to as Segment Income ). These measures should not be considered in isolation or as a substitute for net income, net cash provided by operating activities or other income statement or cash flow statement data prepared in accordance with GAAP or as measures of profitability or liquidity. In addition, these measures, as we determine them, may not be comparable to related or similarly titled measures reported by other companies. The Company accounts for intersegment sales and transfers as if the sales or transfers were to third parties.

49 /ATR

2009 Form 10-K

---

**Table of Contents**

Financial information regarding the Company's reportable segments is shown below:

<b>Years Ended December 31,</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>
Total Sales:			
Beauty & Home	\$ 932,382	\$ 1,086,413	\$ 1,015,694
Closures	491,071	542,711	495,028
Pharma	430,888	458,009	394,320
Other	195	322	1,534
Total Sales	\$ 1,854,536	\$ 2,087,455	\$ 1,906,576
Less: Intersegment Sales:			
Beauty & Home	\$ 11,712	\$ 13,935	\$ 10,476
Closures	523	966	2,028
Pharma	492	553	452
Other	193	316	1,453
Total Intersegment Sales	\$ 12,920	\$ 15,770	\$ 14,409
Net Sales:			
Beauty & Home	\$ 920,669	\$ 1,072,478	\$ 1,005,218
Closures	490,548	541,745	493,000
Pharma	430,397	457,456	393,868
Other	2	6	81
Net Sales	\$ 1,841,616	\$ 2,071,685	\$ 1,892,167
Segment Income:			
Beauty & Home	\$ 58,844	\$ 89,724	\$ 95,635
Closures	49,769	43,934	48,217
Pharma	123,654	129,591	105,974
Corporate and Other (1)	(35,057)	(30,956)	(37,171)
Income from continuing operations before interest and taxes	\$ 197,210	\$ 232,293	\$ 212,655
Interest expense, net	(13,152)	(5,567)	(10,574)
Income from continuing operations before income taxes	\$ 184,058	\$ 226,726	\$ 202,081
Depreciation and Amortization:			
Beauty & Home	\$ 74,865	\$ 76,117	\$ 71,752
Closures	31,564	30,696	29,341
Pharma	23,685	22,231	20,894
Other	2,899	2,101	1,479
Depreciation and Amortization	\$ 133,013	\$ 131,145	\$ 123,466

Capital Expenditures:						
Beauty & Home	\$	<b>60,304</b>	\$	87,191	\$	63,089
Closures		<b>32,526</b>		37,766		37,114
Pharma		<b>26,666</b>		46,729		27,748
Other		<b>25,430</b>		31,914		9,993
Capital Expenditures	\$	<b>144,926</b>	\$	203,600	\$	137,944
Total Assets:						
Beauty & Home	\$	<b>925,183</b>	\$	946,592	\$	993,703
Closures		<b>350,156</b>		354,357		352,573
Pharma		<b>344,581</b>		318,863		289,785
Other		<b>336,273</b>		212,010		275,889
Total Assets	\$	<b>1,956,193</b>	\$	1,831,822	\$	1,911,950

(1) Corporate Expenses & Other includes \$9.8 million, \$11.1 million, and \$14.0 million related to stock option expenses for the twelve months ended December 31, 2009, 2008, and 2007 respectively. These amounts also include \$0.4 million of LIFO expense in 2009, \$2.3 million of LIFO income in 2008 and \$2.3 million of LIFO expense in 2007.

50 /ATR

2009 Form 10-K

**Table of Contents****GEOGRAPHIC INFORMATION**

The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2009, 2008 and 2007:

	<b>2009</b>	<b>2008</b>	<b>2007</b>
Net Sales to Unaffiliated Customers (2):			
United States	\$ <b>519,671</b>	\$ 531,054	\$ 498,231
Europe:			
France	<b>483,051</b>	615,470	536,694
Germany	<b>240,302</b>	284,043	265,246
Italy	<b>129,257</b>	156,704	157,791
Other Europe	<b>220,425</b>	232,450	220,712
Total Europe	<b>1,073,035</b>	1,288,667	1,180,443
Other Foreign Countries	<b>248,910</b>	251,964	213,493
Total	\$ <b>1,841,616</b>	\$ 2,071,685	\$ 1,892,167
Long-Lived Assets:			
United States	\$ <b>263,126</b>	\$ 258,283	\$ 225,074
Europe:			
France	<b>292,927</b>	291,078	262,109
Germany	<b>187,039</b>	168,729	168,096
Italy	<b>91,632</b>	90,389	99,581
Other Europe	<b>99,894</b>	98,794	89,118
Total Europe	<b>671,492</b>	648,990	618,904
Other Foreign Countries	<b>75,717</b>	60,661	61,971
Total	\$ <b>1,010,335</b>	\$ 967,934	\$ 905,949
Product Net Sales Information:			
Pumps	\$ <b>895,188</b>	\$ 998,913	\$ 948,855
Closures	<b>465,001</b>	499,434	455,650
Valves	<b>277,641</b>	309,034	281,831
Other	<b>203,786</b>	264,304	205,831
Total	\$ <b>1,841,616</b>	\$ 2,071,685	\$ 1,892,167

(2) Sales are attributed to countries based upon where the sales invoice to unaffiliated customers is generated.

No single customer represents 10% or more of the Company's net sales in 2009, 2008 or 2007.

NOTE 18 ACQUISITIONS

In August 2009, the Company acquired Covit do Brasil Componentes de Alumínio para Perfumaria Ltda. (Covit do Brasil) for approximately \$7.6 million in cash. Covit do Brasil has been operating in Brazil since 2005 developing and supplying anodized aluminum parts primarily for the fragrance/cosmetic market. Covit do Brasil generally supplies parts to other companies within AptarGroup. No debt was assumed in the transaction. Covit do Brasil's annual revenues are approximately \$7.0 million, of which approximately \$6.0 million are with AptarGroup subsidiaries. The excess purchase price over the fair value of assets acquired was allocated to Goodwill. Goodwill of approximately \$0.7 million was recorded on the transaction. The results of operations subsequent to the acquisition are included in the reported income statement. Covit do Brasil is included in the Beauty and Home reporting segment.

In October 2008, the Company purchased the remaining 50% that it did not already own of Seaplast S.A. for approximately \$6.3 million in cash. Seaplast S.A. is located in Spain and primarily produces dispensing closures. The consolidated statement of income includes Seaplast S.A.'s results of operations from October 29, 2008, the date of the acquisition. Prior to this date, 50% of Seaplast S.A.'s results were included in equity and results from affiliates. Goodwill of approximately \$2.6 million was recorded on the transaction. Seaplast S.A. is included in the Closures reporting segment.

In April 2008, the Company acquired the equipment, inventory and intellectual property of CCL Industries Bag-on-Valve business ( CCLBOV ) for approximately \$9.3 million in cash. No debt was assumed in the transaction. CCLBOV's annual revenues are approximately \$9.0 million. The excess purchase price over the fair value of assets acquired was allocated to Goodwill. Goodwill of approximately \$3.4 million was recorded on the transaction. CCLBOV was located in Canada but the assets purchased were transferred to existing AptarGroup facilities in the U.S. before the end of the second quarter 2008. CCLBOV is included in the Beauty & Home reporting segment.

51 /ATR

2009 Form 10-K

---

**Table of Contents**

At the end of March 2008, the Company acquired 70% of the outstanding shares of Next Breath LLC ( Next Breath ) for approximately \$4.1 million in cash. No debt was assumed in the transaction. Next Breath, located in Baltimore, Maryland, is a contract service organization specializing in analytical testing of nasal and inhalation products on behalf of pharmaceutical, biotech, drug delivery and device companies. Next Breath's annual sales are approximately \$2.0 million. The excess purchase price over the fair value of assets acquired and liabilities assumed was allocated to Goodwill. Goodwill of approximately \$3.7 million was recorded on the transaction. Next Breath is included in the Pharma reporting segment.

None of these acquisitions had a material impact on the results of operations in 2009 or 2008 and therefore no proforma information is required.

**NOTE 19 QUARTERLY DATA (UNAUDITED)**

Quarterly results of operations and per share information for the years ended December 31, 2009 and 2008 are as follows:

	<b>First</b>	<b>Quarter Second</b>	<b>Third</b>	<b>Fourth</b>	<b>Total for Year</b>
<b>Year Ended December 31, 2009:</b>					
<b>Net sales</b>	<b>\$ 431,816</b>	<b>\$ 440,508</b>	<b>\$ 473,668</b>	<b>\$ 495,624</b>	<b>\$ 1,841,616</b>
<b>Gross profit (1)</b>	<b>113,020</b>	<b>118,899</b>	<b>120,233</b>	<b>130,619</b>	<b>482,771</b>
<b>Net Income</b>	<b>26,595</b>	<b>28,470</b>	<b>33,467</b>	<b>36,065</b>	<b>124,597</b>
<b>Per Common Share 2009:</b>					
<b>Net income</b>					
<b>Basic</b>	<b>\$ .39</b>	<b>\$ .42</b>	<b>\$ .49</b>	<b>\$ .53</b>	<b>\$ 1.84</b>
<b>Diluted</b>	<b>.38</b>	<b>.41</b>	<b>.48</b>	<b>.52</b>	<b>1.79</b>
<b>Dividends declared</b>	<b>.15</b>	<b>.15</b>	<b>.15</b>	<b>.15</b>	<b>.60</b>
<b>Stock price high (2)</b>	<b>36.08</b>	<b>34.26</b>	<b>38.09</b>	<b>38.96</b>	<b>38.96</b>
<b>Stock price low (2)</b>	<b>24.95</b>	<b>28.61</b>	<b>32.14</b>	<b>34.52</b>	<b>24.95</b>
<b>Average number of shares outstanding:</b>					
<b>Basic</b>	<b>67,677</b>	<b>67,705</b>	<b>67,691</b>	<b>67,500</b>	<b>67,643</b>
<b>Diluted</b>	<b>69,519</b>	<b>69,293</b>	<b>69,489</b>	<b>69,319</b>	<b>69,785</b>
<b>Year Ended December 31, 2008:</b>					
<b>Net sales</b>	<b>\$ 532,258</b>	<b>\$ 551,319</b>	<b>\$ 532,180</b>	<b>\$ 455,928</b>	<b>\$ 2,071,685</b>
<b>Gross profit (1)</b>	<b>137,751</b>	<b>145,305</b>	<b>134,305</b>	<b>118,164</b>	<b>535,525</b>
<b>Net Income</b>	<b>36,901</b>	<b>45,273</b>	<b>39,651</b>	<b>31,670</b>	<b>153,495</b>
<b>Per Common Share 2008:</b>					
<b>Net income</b>					
<b>Basic</b>	<b>\$ .54</b>	<b>\$ .67</b>	<b>\$ .59</b>	<b>\$ .47</b>	<b>\$ 2.26</b>
<b>Diluted</b>	<b>.52</b>	<b>.64</b>	<b>.57</b>	<b>.46</b>	<b>2.18</b>
<b>Dividends declared</b>	<b>.13</b>	<b>.13</b>	<b>.15</b>	<b>.15</b>	<b>.56</b>
<b>Stock price high (2)</b>	<b>42.72</b>	<b>46.19</b>	<b>44.03</b>	<b>39.75</b>	<b>46.19</b>

Edgar Filing: APTARGROUP INC - Form 10-K

Stock price low (2)	32.87	38.98	30.70	23.74	23.74
Average number of shares outstanding:					
Basic	68,168	68,038	67,670	67,535	67,851
Diluted	71,072	70,563	69,937	69,225	70,518

(1) Gross profit is defined as net sales less cost of sales and depreciation.

(2) The stock price high and low amounts are based upon intra-day New York Stock Exchange composite price history.

52 /ATR

2009 Form 10-K

---



**Table of Contents****NOTE 20 FAIR VALUE**

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3: Unobservable inputs reflecting management's own assumptions about the inputs used in pricing the asset or liability.

As of December 31, 2009, the fair values of our financial assets and liabilities were categorized as follows:

	<b>Total</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
<b><i>Assets</i></b>				
Interest rate swap (a)	\$ 574	\$	\$ 574	\$
Forward exchange contracts (b)	902		902	
Total assets at fair value	\$ 1,476	\$	\$ 1,476	\$
<b><i>Liabilities</i></b>				
Forward exchange contracts (b)	\$ 3,635	\$	\$ 3,635	\$
Total liabilities at fair value	\$ 3,635	\$	\$ 3,635	\$

As of December 31, 2008, the fair values of our financial assets and liabilities were categorized as follows:

	<b>Total</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
<b><i>Assets</i></b>				
Interest rate swap (a)	\$ 1,068	\$	\$ 1,068	\$
Forward exchange contracts (b)	10,865		10,865	
Total assets at fair value	\$ 11,933	\$	\$ 11,933	\$
<b><i>Liabilities</i></b>				
Forward exchange contracts (b)	\$ 1,195	\$	\$ 1,195	\$
Total liabilities at fair value	\$ 1,195	\$	\$ 1,195	\$

(a) Based on third party quotation from financial institution

(b) Based on observable market transactions of spot and forward rates

Based on the variable borrowing rates currently available to the Company for long-term obligations with similar terms and average maturities, the fair value of the Company's long-term obligations approximates its book value.

**NOTE 21 FACILITIES CONSOLIDATION AND SEVERANCE**

In the second quarter of 2009, the Company announced a plan to consolidate two French dispensing closure manufacturing facilities and several sales offices in North America and Europe. The total costs associated with the consolidation/severance programs are estimated to be approximately \$8 million, of which \$7.6 million was recorded during 2009. The majority of the remaining costs are expected to be recorded as incurred in the first half of 2010. All charges related to the facilities consolidation and severance program are reported separately in the income statement. As of December 31, 2009 we have recorded the following pre-tax charges associated with our consolidation/severance programs within the Condensed Consolidated Statements of Income:

	<b>Beginning Reserve at 1/01/09</b>	<b>Charges For The Year Ended 12/31/09</b>	<b>Cash Paid</b>	<b>FX Impact</b>	<b>Ending Reserve at 12/31/09</b>
Employee severance	\$	\$ 6,034	\$ (2,191)	\$ (27)	\$ 3,816
Other costs		1,529	(902)	(8)	619
Totals	\$	\$ 7,563	\$ (3,093)	\$ (35)	\$ 4,435

53 /ATR

2009 Form 10-K

**Table of Contents**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Stockholders of AptarGroup, Inc.:

In our opinion, the consolidated financial statements listed in the index appearing under Item 15(a)(1) present fairly, in all material respects, the financial position of AptarGroup, Inc. and its subsidiaries at December 31, 2009 and December 31, 2008, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2009 in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion, the financial statement schedule listed in the index appearing under Item 15(a)(2) presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2009, based on criteria established in *Internal Control Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial statements and financial statement schedule, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting, under Item 9A. Our responsibility is to express opinions on these financial statements, on the financial statement schedule, and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As discussed in Note 6, to the consolidated financial statements, the Company changed the manner in which it accounts for uncertain tax positions in 2007.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Chicago, Illinois  
February 26, 2010

54 /ATR

2009 Form 10-K

---

**Table of Contents**

**ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON  
ACCOUNTING AND FINANCIAL DISCLOSURE**

None.

**ITEM 9A. CONTROLS AND PROCEDURES**

**DISCLOSURE CONTROLS AND PROCEDURES**

The Company's management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of December 31, 2009. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

**MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. The Company's management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of our internal control over financial reporting as of December 31, 2009 based on the framework in *Internal Control - Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation under the framework in *Internal Control - Integrated Framework*, management has concluded that our internal control over financial reporting was effective as of December 31, 2009. PricewaterhouseCoopers LLP, independent registered public accounting firm, has issued an attestation report on the effectiveness of our internal control over financial reporting. This report appears on page 57.

**CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING**

No change in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during the Company's fiscal quarter ended December 31, 2009 that materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**ITEM 9B. OTHER INFORMATION**

None.

**PART III**

Certain information required to be furnished in this part of the Form 10-K has been omitted because the Company will file with the Securities and Exchange Commission a definitive proxy statement pursuant to Regulation 14A under the Securities Exchange Act of 1934 no later than April 30, 2010.

**ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**

Information with respect to directors may be found under the caption "Proposal 1 Election of Directors" in the Company's Proxy Statement for the Annual Meeting of Stockholders to be held on May 5, 2010 (the "2010 Proxy Statement") and is incorporated herein by reference.

Information with respect to executive officers may be found under the caption "Executive Officers" in Part I of this report and is incorporated herein by reference.

Information with respect to audit committee members and audit committee financial experts may be found under the caption "Corporate Governance Audit Committee" in the 2010 Proxy Statement and is incorporated herein by reference.

Information with respect to the Company's Code of Business Conduct and Ethics may be found under the caption "Corporate Governance Code of Business Conduct and Ethics" in the 2010 Proxy Statement and is incorporated herein by reference. Our Code of Business Conduct and Ethics is available through the Corporate Governance link on the Investor Relations page of our website ([www.aptar.com](http://www.aptar.com)).

The information set forth under the heading "Section 16(a) Beneficial Ownership Reporting Compliance" in the 2010 Proxy Statement is incorporated herein by reference.

55 /ATR

2009 Form 10-K

---

**Table of Contents**

**ITEM 11. EXECUTIVE COMPENSATION**

The information set forth under the headings Board Compensation , Executive Officer Compensation and Compensation Committee Report in the 2010 Proxy Statement is incorporated herein by reference. The information included under the heading Compensation Committee Report in the 2010 Proxy Statement shall not be deemed to be soliciting material or to be filed with the Securities and Exchange Commission or subject to Regulation 14A or 14C, or to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended.

**ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

The information set forth under the heading Security Ownership of Certain Beneficial Owners, Directors and Management and Equity Compensation Plan Information in the 2010 Proxy Statement is incorporated herein by reference.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

The information set forth under the heading Transactions with Related Persons and Corporate Governance Independence of Directors in the 2010 Proxy Statement is incorporated herein by reference.

**ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES**

Information with respect to the independent registered public accounting firm fees and services may be found under the caption Proposal 2 Ratification of the Appointment of the Independent Registered Public Accounting Firm in the 2010 Proxy Statement. Such information is incorporated herein by reference.

PART IV

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

(a) The following documents are filed as a part of this report:

Description	
1) <i>All Financial Statements</i>	
The financial statements are set forth under Item 8 of this report on Form 10-K	
Consolidated Statements of Income	27
Consolidated Balance Sheets	28
Consolidated Statements of Cash Flows	30
Consolidated Statements of Changes in Equity	31
Notes to Consolidated Financial Statements	32
Report of Independent Registered Public Accounting Firm	54
2) <i>II Valuation and Qualifying Accounts</i>	58

All other schedules have been omitted because they are not applicable or not required.

- (b) Exhibits required by Item 601 of Regulation S-K are incorporated by reference to the Exhibit Index on pages 58-60 of this report.

56 /ATR

2009 Form 10-K

---



**Table of Contents**

## SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized in the City of Crystal Lake, State of Illinois on this 26th day of February 2010.

AptarGroup, Inc.  
(Registrant)

By /s/ Robert W. Kuhn

Robert W. Kuhn  
Executive Vice President and  
Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the date indicated.

Signature	Title	Date
/s/ King Harris King Harris	Chairman of the Board and Director	February 26, 2010
/s/ Peter Pfeiffer Peter Pfeiffer	President and Chief Executive Officer and Director (Principal Executive Officer)	February 26, 2010
/s/ Stephen J. Hagge Stephen J. Hagge	Executive Vice President, Chief Operating Officer, and Director	February 26, 2010
/s/ Robert W. Kuhn Robert W. Kuhn	Executive Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)	February 26, 2010
/s/ Stefan A. Baustert Stefan A. Baustert	Director	February 26, 2010
/s/ Alain Chevassus Alain Chevassus	Director	February 26, 2010
/s/ Rodney L. Goldstein	Director	February 26, 2010

Edgar Filing: APTARGROUP INC - Form 10-K

Rodney L. Goldstein

/s/ Leo A. Guthart

Director

February 26, 2010

Leo A. Guthart

/s/ Carl A. Siebel

Director

February 26, 2010

Carl A. Siebel

/s/ Dr. Joanne C. Smith

Director

February 26, 2010

Dr. Joanne C. Smith

/s/ Ralf Wunderlich

Director

February 26, 2010

Ralf Wunderlich

57 /ATR

2009 Form 10-K

---

**Table of Contents**

**AptarGroup, Inc.**  
**SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS**

For the years ended December 31, 2009, 2008 and 2007

**Dollars in thousands**

	<b>Balance at Beginning Of Period</b>	<b>Charged to Costs and Expenses</b>	<b>Acquisitions</b>	<b>Deductions from Reserve (a)</b>	<b>Balance at End of Period</b>
<b>2009</b>					
Allowance for doubtful accounts	\$ 11,900	\$ 701	\$	\$ (2,678)	\$ 9,923
Inventory obsolescence reserve	26,782	5,877	87	(9,303)	23,443
Deferred tax valuation allowance	2,903	2,577			5,480
<b>2008</b>					
Allowance for doubtful accounts	\$ 11,139	\$ 3,063	\$	\$ (2,302)	\$ 11,900
Inventory obsolescence reserve	27,079	5,880		(6,177)	26,782
Deferred tax valuation allowance	4,396			(1,493)	2,903
<b>2007</b>					
Allowance for doubtful accounts	\$ 10,963	\$ 1,970	\$	\$ (1,794)	\$ 11,139
Inventory obsolescence reserve	24,104	5,912		(2,937)	27,079
Deferred tax valuation allowance	3,282	1,114			4,396

(a) Write-off accounts considered uncollectible, net of recoveries and foreign currency transaction adjustments.

(a) INDEX TO EXHIBITS

**Exhibit****Number Description**

- 3(i) Amended and Restated Certificate of Incorporation of AptarGroup, Inc., as amended, filed as Exhibit 4(a) to AptarGroup Inc.'s Registration Statement on Form S-8, Registration Number 333-152525, filed on July 25, 2008 (the Form S-8), is hereby incorporated by reference.
- 3(ii) Amended and Restated By-Laws of the Company, filed as Exhibit 3(ii) to the Company's Annual Report on Form 10-K for the year ended December 31, 2002 (File No. 1-11846), is hereby incorporated by reference.
- 4.1 Rights Agreement dated as of April 7, 2003 between the Company and Wells Fargo, as successor rights agent, which includes the Form of Rights Certificate as Exhibit B, filed as Exhibit 1 to the Company's Registration Statement on Form 8-A filed on April 7, 2003 (File No. 1-11846), is hereby incorporated by reference.
- 4.2 Certificate of Designation to the Series B Junior Participating Preferred Stock of the Company, dated April 7, 2003, filed as Exhibit 2 of the Company's Registration Statement on Form 8-A filed on April 7, 2003 (File No. 1-11846), is hereby incorporated by reference.

## Edgar Filing: APTARGROUP INC - Form 10-K

The Company hereby agrees to provide the Commission, upon request, copies of instruments defining the rights of holders of long-term debt of the Registrant and its subsidiaries as are specified by item 601(b)(4)(iii)(A) of Regulation S-K.

- 4.3 Note Purchase Agreement dated as of May 15, 1999 relating to \$107 million senior unsecured notes, series 1999-A, filed as Exhibit 4.1 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 1999 (File No. 1-11846), is hereby incorporated by reference.
- 4.4 Amended and Restated Multicurrency Credit Agreement dated as of July 31, 2006 among AptarGroup, Inc., and AptarGroup Holding SAS, as borrowers, the lenders from time to time party thereto, Bank of America, N.A. as Administrative Agent, Banc of America Securities LLC as Sole Lead Arranger and Banc of America Securities LLC and JP Morgan Securities Inc. as Joint Bookrunners, filed as Exhibit 4.1 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2006 (File No. 1-11846), is hereby incorporated by reference.
- 4.5 Note Purchase Agreement dated as of July 31, 2006, among AptarGroup, Inc. and the purchasers listed on Schedule A thereto, filed as Exhibit 4.2 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2006 (File No. 1-11846), is hereby incorporated by reference.
- 4.6 Form of AptarGroup, Inc. 6.04% Series 2006-A Senior Notes Due July 31, 2016, filed as Exhibit 4.3 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2006 (File No. 1-11846), is hereby incorporated by reference.
- 4.7 Note Purchase Agreement dated as of July 31, 2008, among AptarGroup, Inc. and the purchasers listed on Schedule A thereto, filed as Exhibit 4.1 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.

58 /ATR

2009 Form 10-K

---

**Table of Contents****Exhibit****Number Description**

- 4.8 Form of AptarGroup, Inc. 5.41% Series 2008-A-1 Senior Notes Due July 31, 2013, filed as Exhibit 4.2 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.
- 4.9 Form of AptarGroup, Inc. 6.03% Series 2008-A-2 Senior Notes Due July 31, 2018, filed as Exhibit 4.2 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.
- 10.1 AptarGroup, Inc. 1996 Stock Awards Plan, filed as Appendix A to the Company's Proxy Statement, dated April 10, 1996 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.2 AptarGroup, Inc. 1996 Director Stock Option Plan, filed as Appendix B to the Company's Proxy Statement, dated April 10, 1996 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.3 AptarGroup, Inc. 2000 Stock Awards Plan, filed as Appendix A to the Company's Proxy Statement, dated April 6, 2000 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.4 AptarGroup, Inc. 2000 Director Stock Option Plan, filed as Appendix B to the Company's Proxy Statement, dated April 6, 2000 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.5 AptarGroup, Inc. 2004 Stock Awards Plan, filed as Appendix A to the Company's Proxy Statement, dated March 26, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.6 AptarGroup, Inc. 2004 Director Stock Option Plan, filed as Appendix B to the Company's Proxy Statement, dated March 26, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.7 AptarGroup, Inc., Stock Option Agreement for Employees pursuant to the AptarGroup, Inc. 2004 Stock Awards Plan, filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.8 AptarGroup, Inc. Stock Option Agreement for Non-Employee Directors pursuant to the AptarGroup, Inc. 2004 Director Option Plan, filed as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.9 AptarGroup, Inc. Stock Option Agreement for Employees pursuant to the AptarGroup, Inc. 2000 Stock Awards Plan, filed as Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.10 AptarGroup, Inc. Restricted Stock Unit Award Agreement pursuant to the AptarGroup, Inc. 2000 Stock Awards Plan, filed as Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.11 Supplementary Pension Plan - France dated August 24, 2001, filed as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.12 AptarGroup, Inc. Supplemental Retirement Plan dated October 6, 2008, filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.13 Employment Agreement dated October 17, 2007 of Peter Pfeiffer, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 17, 2007 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.14 German Employment Agreement dated October 17, 2007 of Peter Pfeiffer, filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on October 17, 2007 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.15 Service Agreement dated April 30, 1981, of Carl A. Siebel, and related pension plan, filed as Exhibit 10.5 to the Company's Registration Statement on Form S-1, Registration Number 33-58132, filed February 10,

Edgar Filing: APTARGROUP INC - Form 10-K

- 1993, is hereby incorporated by reference.\*\*
- 10.16 First supplement dated 1989 pertaining to the pension plan between Perfect-Valois Ventil GmbH and Carl A. Siebel, filed as Exhibit 10.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 1993 (file No. 1-11846), is hereby incorporated by reference.\*\*
- 10.17 Second supplement dated December 19, 1994 pertaining to the pension plan between Perfect-Valois Ventil GmbH and Carl A. Siebel, filed as Exhibit 10.11 of the Company's Annual Report on Form 10-K for the year ended December 31, 1994 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.18 Supplement to the Pension Scheme Arrangement dated October 17, 2007 pertaining to the pension plan between a subsidiary of AptarGroup, Inc. and Peter Pfeiffer, filed as Exhibit 10.3 to the Company's Current Report on Form 8-K filed on October 17, 2007 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.19 Consulting Agreement between AptarGroup, Inc. and Carl Siebel Consulting GmbH dated October 17, 2007, filed as Exhibit 10.4 to the Company's Current Report on Form 8-K filed on October 17, 2007 (File No. 1-11846), is hereby incorporated by reference.\*\*
- 10.20 First amendment to Consulting Agreement between AptarGroup, Inc. and Carl Siebel Consulting GmbH dated October 30, 2009, filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 (File No. 1-11846), is hereby incorporated by reference.\*\*

59 /ATR

2009 Form 10-K

---

**Table of Contents****Exhibit**

<b>Number</b>	<b>Description</b>
10.21	Indemnification Agreement dated January 1, 1996 of King Harris, filed as Exhibit 10.25 to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2001 (File No. 1-11846), is hereby incorporated by reference.**
10.22	Employment Agreement dated July 18, 2008 of Stephen J. Hagge, filed as Exhibit 10.7 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.23	Employment Agreement dated July 18, 2008 of Eric Ruskoski, filed as Exhibit 10.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.24	Notice of termination of automatic extension of Employment Agreement of Eric Ruskoski dated October 30, 2009, filed as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 (File No. 1-11846), is hereby incorporated by reference.**
10.25	Employment Agreement dated January 18, 2008 of Olivier Fourment filed as Exhibit 10.9 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.26	Employment Agreement dated January 18, 2008 of Olivier de Pous filed as Exhibit 10.10 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.27*	Employment Agreement dated December 1, 2003 and amended and restated as of July 18, 2008 of Patrick F. Doherty filed herewith.**
10.28	Severance Agreement dated July 18, 2008 of Robert Kuhn filed as Exhibit 10.2 to the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.29	AptarGroup, Inc. Annual Bonus Plan, filed as Exhibit 10.2 to AptarGroup, Inc.'s Current Report on Form 8-K filed on May 1, 2008, is hereby incorporated by reference.**
10.30	AptarGroup, Inc. 2008 Stock Option Plan, filed as Exhibit 10.3 to AptarGroup, Inc.'s Current Report on Form 8-K filed on May 1, 2008, is hereby incorporated by reference.**
10.31	AptarGroup, Inc. 2008 Director Stock Option Plan, filed as Exhibit 10.1 to AptarGroup, Inc.'s Current Report on Form 8-K filed on May 1, 2008, is hereby incorporated by reference.**
10.32	Form of AptarGroup, Inc. Stock Option Agreement for Employees pursuant to the AptarGroup, Inc. 2008 Stock Option Plan filed as Exhibit 10.4 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.33	Form of AptarGroup, Inc. Stock Option Agreement for Non-Employee Directors pursuant to the AptarGroup, Inc. 2008 Director Stock Option Plan filed as Exhibit 10.5 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), is hereby incorporated by reference.**
10.34*	Form of AptarGroup, Inc. Restricted Stock Unit Award Agreement pursuant to the AptarGroup, Inc. 2004 Stock Awards Plan, filed as Exhibit 10.6 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 1-11846), and amended as of January 1, 2010, filed herewith.**
21*	List of Subsidiaries.
23*	Consent of Independent Registered Public Accounting Firm.
31.1*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	

Edgar Filing: APTARGROUP INC - Form 10-K

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2\* Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

\* Filed herewith.

\*\* Management contract or compensatory plan or arrangement.

60 /ATR

2009 Form 10-K